Urologix, Inc.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, ABT has a market cap of 231.80B. Regarding current trading prices, ULGX is priced at $0.00, while ABT trades at $133.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas ABT's P/E ratio is 17.30. In terms of profitability, ULGX's ROE is +2.32%, compared to ABT's ROE of +0.24%. Regarding short-term risk, ULGX is less volatile compared to ABT. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, BSX-PA has a market cap of 175.45B. Regarding current trading prices, ULGX is priced at $0.00, while BSX-PA trades at $122.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, ULGX's ROE is +2.32%, compared to BSX-PA's ROE of +0.10%. Regarding short-term risk, ULGX is less volatile compared to BSX-PA. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, BSX has a market cap of 152.15B. Regarding current trading prices, ULGX is priced at $0.00, while BSX trades at $102.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas BSX's P/E ratio is 75.07. In terms of profitability, ULGX's ROE is +2.32%, compared to BSX's ROE of +0.10%. Regarding short-term risk, ULGX is less volatile compared to BSX. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, SYK has a market cap of 145.63B. Regarding current trading prices, ULGX is priced at $0.00, while SYK trades at $381.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas SYK's P/E ratio is 51.43. In terms of profitability, ULGX's ROE is +2.32%, compared to SYK's ROE of +0.11%. Regarding short-term risk, ULGX is less volatile compared to SYK. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, SMMNY has a market cap of 118.71B. Regarding current trading prices, ULGX is priced at $0.00, while SMMNY trades at $26.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas SMMNY's P/E ratio is 26.46. In terms of profitability, ULGX's ROE is +2.32%, compared to SMMNY's ROE of +0.11%. Regarding short-term risk, ULGX is less volatile compared to SMMNY. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, MDT has a market cap of 107.05B. Regarding current trading prices, ULGX is priced at $0.00, while MDT trades at $83.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas MDT's P/E ratio is 25.45. In terms of profitability, ULGX's ROE is +2.32%, compared to MDT's ROE of +0.09%. Regarding short-term risk, ULGX is less volatile compared to MDT. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, SEMHF has a market cap of 57.98B. Regarding current trading prices, ULGX is priced at $0.00, while SEMHF trades at $51.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas SEMHF's P/E ratio is 25.85. In terms of profitability, ULGX's ROE is +2.32%, compared to SEMHF's ROE of +0.11%. Regarding short-term risk, ULGX is less volatile compared to SEMHF. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, EW has a market cap of 43.22B. Regarding current trading prices, ULGX is priced at $0.00, while EW trades at $73.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas EW's P/E ratio is 30.45. In terms of profitability, ULGX's ROE is +2.32%, compared to EW's ROE of +0.49%. Regarding short-term risk, ULGX is less volatile compared to EW. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, DXCM has a market cap of 33.20B. Regarding current trading prices, ULGX is priced at $0.00, while DXCM trades at $84.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas DXCM's P/E ratio is 63.66. In terms of profitability, ULGX's ROE is +2.32%, compared to DXCM's ROE of +0.24%. Regarding short-term risk, ULGX is less volatile compared to DXCM. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, PHG has a market cap of 22.71B. Regarding current trading prices, ULGX is priced at $0.00, while PHG trades at $24.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas PHG's P/E ratio is 84.66. In terms of profitability, ULGX's ROE is +2.32%, compared to PHG's ROE of -0.06%. Regarding short-term risk, ULGX is less volatile compared to PHG. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, RYLPF has a market cap of 22.69B. Regarding current trading prices, ULGX is priced at $0.00, while RYLPF trades at $24.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas RYLPF's P/E ratio is 81.78. In terms of profitability, ULGX's ROE is +2.32%, compared to RYLPF's ROE of -0.06%. Regarding short-term risk, ULGX is less volatile compared to RYLPF. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, STE has a market cap of 22.25B. Regarding current trading prices, ULGX is priced at $0.00, while STE trades at $226.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas STE's P/E ratio is 36.47. In terms of profitability, ULGX's ROE is +2.32%, compared to STE's ROE of +0.07%. Regarding short-term risk, ULGX is less volatile compared to STE. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, PODD has a market cap of 21.86B. Regarding current trading prices, ULGX is priced at $0.00, while PODD trades at $310.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas PODD's P/E ratio is 53.66. In terms of profitability, ULGX's ROE is +2.32%, compared to PODD's ROE of +0.41%. Regarding short-term risk, ULGX is less volatile compared to PODD. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, ZBH has a market cap of 18.84B. Regarding current trading prices, ULGX is priced at $0.00, while ZBH trades at $95.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas ZBH's P/E ratio is 21.16. In terms of profitability, ULGX's ROE is +2.32%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, ULGX is less volatile compared to ZBH. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, SONVF has a market cap of 18.83B. Regarding current trading prices, ULGX is priced at $0.00, while SONVF trades at $315.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas SONVF's P/E ratio is 27.50. In terms of profitability, ULGX's ROE is +2.32%, compared to SONVF's ROE of +0.26%. Regarding short-term risk, ULGX and SONVF have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, SONVY has a market cap of 18.80B. Regarding current trading prices, ULGX is priced at $0.00, while SONVY trades at $63.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas SONVY's P/E ratio is 27.43. In terms of profitability, ULGX's ROE is +2.32%, compared to SONVY's ROE of +0.26%. Regarding short-term risk, ULGX is less volatile compared to SONVY. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, ABMD has a market cap of 17.18B. Regarding current trading prices, ULGX is priced at $0.00, while ABMD trades at $381.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas ABMD's P/E ratio is 65.36. In terms of profitability, ULGX's ROE is +2.32%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, ULGX is less volatile compared to ABMD. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, ALGN has a market cap of 13.32B. Regarding current trading prices, ULGX is priced at $0.00, while ALGN trades at $181.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas ALGN's P/E ratio is 33.13. In terms of profitability, ULGX's ROE is +2.32%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, ULGX is less volatile compared to ALGN. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, SWAV has a market cap of 12.57B. Regarding current trading prices, ULGX is priced at $0.00, while SWAV trades at $334.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas SWAV's P/E ratio is 78.76. In terms of profitability, ULGX's ROE is +2.32%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, ULGX is less volatile compared to SWAV. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, SNNUF has a market cap of 12.53B. Regarding current trading prices, ULGX is priced at $0.00, while SNNUF trades at $14.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas SNNUF's P/E ratio is 30.48. In terms of profitability, ULGX's ROE is +2.32%, compared to SNNUF's ROE of +0.08%. Regarding short-term risk, ULGX and SNNUF have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, SNN has a market cap of 12.40B. Regarding current trading prices, ULGX is priced at $0.00, while SNN trades at $28.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas SNN's P/E ratio is 30.15. In terms of profitability, ULGX's ROE is +2.32%, compared to SNN's ROE of +0.08%. Regarding short-term risk, ULGX is less volatile compared to SNN. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, PEN has a market cap of 11.52B. Regarding current trading prices, ULGX is priced at $0.00, while PEN trades at $297.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas PEN's P/E ratio is 278.02. In terms of profitability, ULGX's ROE is +2.32%, compared to PEN's ROE of +0.04%. Regarding short-term risk, ULGX is less volatile compared to PEN. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, CHEOF has a market cap of 11.09B. Regarding current trading prices, ULGX is priced at $0.00, while CHEOF trades at $169.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas CHEOF's P/E ratio is 46.56. In terms of profitability, ULGX's ROE is +2.32%, compared to CHEOF's ROE of +0.20%. Regarding short-term risk, ULGX is less volatile compared to CHEOF. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, CHEOY has a market cap of 10.94B. Regarding current trading prices, ULGX is priced at $0.00, while CHEOY trades at $83.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas CHEOY's P/E ratio is 45.72. In terms of profitability, ULGX's ROE is +2.32%, compared to CHEOY's ROE of +0.20%. Regarding short-term risk, ULGX is less volatile compared to CHEOY. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, WILYY has a market cap of 8.00B. Regarding current trading prices, ULGX is priced at $0.00, while WILYY trades at $18.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas WILYY's P/E ratio is 18.59. In terms of profitability, ULGX's ROE is +2.32%, compared to WILYY's ROE of +0.25%. Regarding short-term risk, ULGX and WILYY have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, GMED has a market cap of 7.55B. Regarding current trading prices, ULGX is priced at $0.00, while GMED trades at $55.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas GMED's P/E ratio is 74.41. In terms of profitability, ULGX's ROE is +2.32%, compared to GMED's ROE of +0.03%. Regarding short-term risk, ULGX is less volatile compared to GMED. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, WILLF has a market cap of 7.46B. Regarding current trading prices, ULGX is priced at $0.00, while WILLF trades at $36.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas WILLF's P/E ratio is 17.95. In terms of profitability, ULGX's ROE is +2.32%, compared to WILLF's ROE of +0.25%. Regarding short-term risk, ULGX and WILLF have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, BIO has a market cap of 6.52B. Regarding current trading prices, ULGX is priced at $0.00, while BIO trades at $239.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas BIO's P/E ratio is -3.12. In terms of profitability, ULGX's ROE is +2.32%, compared to BIO's ROE of -0.32%. Regarding short-term risk, ULGX is less volatile compared to BIO. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, BIO-B has a market cap of 6.33B. Regarding current trading prices, ULGX is priced at $0.00, while BIO-B trades at $234.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas BIO-B's P/E ratio is -3.06. In terms of profitability, ULGX's ROE is +2.32%, compared to BIO-B's ROE of -0.32%. Regarding short-term risk, ULGX and BIO-B have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, BRKR has a market cap of 5.69B. Regarding current trading prices, ULGX is priced at $0.00, while BRKR trades at $37.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas BRKR's P/E ratio is 72.15. In terms of profitability, ULGX's ROE is +2.32%, compared to BRKR's ROE of +0.07%. Regarding short-term risk, ULGX is less volatile compared to BRKR. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, GNGBF has a market cap of 5.37B. Regarding current trading prices, ULGX is priced at $0.00, while GNGBF trades at $21.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas GNGBF's P/E ratio is 37.70. In terms of profitability, ULGX's ROE is +2.32%, compared to GNGBF's ROE of +0.05%. Regarding short-term risk, ULGX is less volatile compared to GNGBF. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, GNGBY has a market cap of 5.26B. Regarding current trading prices, ULGX is priced at $0.00, while GNGBY trades at $19.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas GNGBY's P/E ratio is 34.15. In terms of profitability, ULGX's ROE is +2.32%, compared to GNGBY's ROE of +0.05%. Regarding short-term risk, ULGX is less volatile compared to GNGBY. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, GKOS has a market cap of 5.14B. Regarding current trading prices, ULGX is priced at $0.00, while GKOS trades at $89.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas GKOS's P/E ratio is -39.63. In terms of profitability, ULGX's ROE is +2.32%, compared to GKOS's ROE of -0.17%. Regarding short-term risk, ULGX is less volatile compared to GKOS. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, NARI has a market cap of 4.68B. Regarding current trading prices, ULGX is priced at $0.00, while NARI trades at $79.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas NARI's P/E ratio is -59.24. In terms of profitability, ULGX's ROE is +2.32%, compared to NARI's ROE of -0.18%. Regarding short-term risk, ULGX is less volatile compared to NARI. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, INSP has a market cap of 4.46B. Regarding current trading prices, ULGX is priced at $0.00, while INSP trades at $151.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas INSP's P/E ratio is 69.09. In terms of profitability, ULGX's ROE is +2.32%, compared to INSP's ROE of +0.10%. Regarding short-term risk, ULGX is less volatile compared to INSP. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, IRTC has a market cap of 4.40B. Regarding current trading prices, ULGX is priced at $0.00, while IRTC trades at $137.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas IRTC's P/E ratio is -43.99. In terms of profitability, ULGX's ROE is +2.32%, compared to IRTC's ROE of -1.13%. Regarding short-term risk, ULGX is less volatile compared to IRTC. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, AMBBY has a market cap of 4.14B. Regarding current trading prices, ULGX is priced at $0.00, while AMBBY trades at $15.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas AMBBY's P/E ratio is 74.52. In terms of profitability, ULGX's ROE is +2.32%, compared to AMBBY's ROE of +0.06%. Regarding short-term risk, ULGX and AMBBY have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, ITGR has a market cap of 4.13B. Regarding current trading prices, ULGX is priced at $0.00, while ITGR trades at $118.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas ITGR's P/E ratio is 55.08. In terms of profitability, ULGX's ROE is +2.32%, compared to ITGR's ROE of +0.05%. Regarding short-term risk, ULGX is less volatile compared to ITGR. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, AMBFF has a market cap of 4.13B. Regarding current trading prices, ULGX is priced at $0.00, while AMBFF trades at $17.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas AMBFF's P/E ratio is 84.76. In terms of profitability, ULGX's ROE is +2.32%, compared to AMBFF's ROE of +0.06%. Regarding short-term risk, ULGX is less volatile compared to AMBFF. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, NHNKY has a market cap of 3.93B. Regarding current trading prices, ULGX is priced at $0.00, while NHNKY trades at $11.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas NHNKY's P/E ratio is 16.58. In terms of profitability, ULGX's ROE is +2.32%, compared to NHNKY's ROE of +0.06%. Regarding short-term risk, ULGX is less volatile compared to NHNKY. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, TMDX has a market cap of 3.77B. Regarding current trading prices, ULGX is priced at $0.00, while TMDX trades at $111.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas TMDX's P/E ratio is 104.21. In terms of profitability, ULGX's ROE is +2.32%, compared to TMDX's ROE of +0.18%. Regarding short-term risk, ULGX is less volatile compared to TMDX. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, AXNX has a market cap of 3.63B. Regarding current trading prices, ULGX is priced at $0.00, while AXNX trades at $70.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas AXNX's P/E ratio is -709.80. In terms of profitability, ULGX's ROE is +2.32%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, ULGX and AXNX have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, PRCT has a market cap of 2.94B. Regarding current trading prices, ULGX is priced at $0.00, while PRCT trades at $53.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas PRCT's P/E ratio is -31.43. In terms of profitability, ULGX's ROE is +2.32%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, ULGX is less volatile compared to PRCT. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, NHNKF has a market cap of 2.48B. Regarding current trading prices, ULGX is priced at $0.00, while NHNKF trades at $15.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas NHNKF's P/E ratio is 41.86. In terms of profitability, ULGX's ROE is +2.32%, compared to NHNKF's ROE of +0.06%. Regarding short-term risk, ULGX and NHNKF have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, LIVN has a market cap of 2.40B. Regarding current trading prices, ULGX is priced at $0.00, while LIVN trades at $44.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas LIVN's P/E ratio is -10.83. In terms of profitability, ULGX's ROE is +2.32%, compared to LIVN's ROE of +0.05%. Regarding short-term risk, ULGX is less volatile compared to LIVN. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, VTRLY has a market cap of 2.22B. Regarding current trading prices, ULGX is priced at $0.00, while VTRLY trades at $16.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas VTRLY's P/E ratio is 43.13. In terms of profitability, ULGX's ROE is +2.32%, compared to VTRLY's ROE of +0.04%. Regarding short-term risk, ULGX and VTRLY have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, NUVA has a market cap of 2.08B. Regarding current trading prices, ULGX is priced at $0.00, while NUVA trades at $39.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas NUVA's P/E ratio is 75.00. In terms of profitability, ULGX's ROE is +2.32%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, ULGX is less volatile compared to NUVA. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, STSEY has a market cap of 2.04B. Regarding current trading prices, ULGX is priced at $0.00, while STSEY trades at $6.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas STSEY's P/E ratio is 39.41. In terms of profitability, ULGX's ROE is +2.32%, compared to STSEY's ROE of +0.04%. Regarding short-term risk, ULGX and STSEY have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, GNNDY has a market cap of 2.00B. Regarding current trading prices, ULGX is priced at $0.00, while GNNDY trades at $41.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas GNNDY's P/E ratio is 16.43. In terms of profitability, ULGX's ROE is +2.32%, compared to GNNDY's ROE of +0.08%. Regarding short-term risk, ULGX is less volatile compared to GNNDY. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, SSII has a market cap of 1.95B. Regarding current trading prices, ULGX is priced at $0.00, while SSII trades at $10.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas SSII's P/E ratio is -91.73. In terms of profitability, ULGX's ROE is +2.32%, compared to SSII's ROE of -1.33%. Regarding short-term risk, ULGX is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, GGNDF has a market cap of 1.89B. Regarding current trading prices, ULGX is priced at $0.00, while GGNDF trades at $13.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas GGNDF's P/E ratio is 15.48. In terms of profitability, ULGX's ROE is +2.32%, compared to GGNDF's ROE of +0.08%. Regarding short-term risk, ULGX is less volatile compared to GGNDF. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, UFPT has a market cap of 1.82B. Regarding current trading prices, ULGX is priced at $0.00, while UFPT trades at $236.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas UFPT's P/E ratio is 29.02. In terms of profitability, ULGX's ROE is +2.32%, compared to UFPT's ROE of +0.18%. Regarding short-term risk, ULGX is less volatile compared to UFPT. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, MCRPF has a market cap of 1.79B. Regarding current trading prices, ULGX is priced at $0.00, while MCRPF trades at $0.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas MCRPF's P/E ratio is -8.07. In terms of profitability, ULGX's ROE is +2.32%, compared to MCRPF's ROE of -0.33%. Regarding short-term risk, ULGX is less volatile compared to MCRPF. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, ATEC has a market cap of 1.78B. Regarding current trading prices, ULGX is priced at $0.00, while ATEC trades at $12.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas ATEC's P/E ratio is -10.71. In terms of profitability, ULGX's ROE is +2.32%, compared to ATEC's ROE of -2.58%. Regarding short-term risk, ULGX is less volatile compared to ATEC. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, OSSFF has a market cap of 1.77B. Regarding current trading prices, ULGX is priced at $0.00, while OSSFF trades at $4.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas OSSFF's P/E ratio is 24.41. In terms of profitability, ULGX's ROE is +2.32%, compared to OSSFF's ROE of +0.09%. Regarding short-term risk, ULGX is less volatile compared to OSSFF. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, CNMD has a market cap of 1.77B. Regarding current trading prices, ULGX is priced at $0.00, while CNMD trades at $57.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas CNMD's P/E ratio is 14.98. In terms of profitability, ULGX's ROE is +2.32%, compared to CNMD's ROE of +0.13%. Regarding short-term risk, ULGX is less volatile compared to CNMD. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, DWRKF has a market cap of 1.75B. Regarding current trading prices, ULGX is priced at $0.00, while DWRKF trades at $543.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas DWRKF's P/E ratio is 75.94. In terms of profitability, ULGX's ROE is +2.32%, compared to DWRKF's ROE of N/A. Regarding short-term risk, ULGX and DWRKF have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, OSSUY has a market cap of 1.71B. Regarding current trading prices, ULGX is priced at $0.00, while OSSUY trades at $4.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas OSSUY's P/E ratio is 23.53. In terms of profitability, ULGX's ROE is +2.32%, compared to OSSUY's ROE of +0.09%. Regarding short-term risk, ULGX and OSSUY have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, MEDGF has a market cap of 1.67B. Regarding current trading prices, ULGX is priced at $0.00, while MEDGF trades at $83.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas MEDGF's P/E ratio is 33.30. In terms of profitability, ULGX's ROE is +2.32%, compared to MEDGF's ROE of +0.16%. Regarding short-term risk, ULGX and MEDGF have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, TNDM has a market cap of 1.53B. Regarding current trading prices, ULGX is priced at $0.00, while TNDM trades at $22.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas TNDM's P/E ratio is -8.24. In terms of profitability, ULGX's ROE is +2.32%, compared to TNDM's ROE of -0.83%. Regarding short-term risk, ULGX is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, HSKA has a market cap of 1.31B. Regarding current trading prices, ULGX is priced at $0.00, while HSKA trades at $119.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas HSKA's P/E ratio is -62.49. In terms of profitability, ULGX's ROE is +2.32%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, ULGX and HSKA have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, AORT has a market cap of 1.23B. Regarding current trading prices, ULGX is priced at $0.00, while AORT trades at $28.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas AORT's P/E ratio is -56.67. In terms of profitability, ULGX's ROE is +2.32%, compared to AORT's ROE of -0.07%. Regarding short-term risk, ULGX is less volatile compared to AORT. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, DRWKF has a market cap of 1.19B. Regarding current trading prices, ULGX is priced at $0.00, while DRWKF trades at $67.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas DRWKF's P/E ratio is 9.01. In terms of profitability, ULGX's ROE is +2.32%, compared to DRWKF's ROE of +0.09%. Regarding short-term risk, ULGX is less volatile compared to DRWKF. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, AHCO has a market cap of 1.16B. Regarding current trading prices, ULGX is priced at $0.00, while AHCO trades at $8.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas AHCO's P/E ratio is 14.78. In terms of profitability, ULGX's ROE is +2.32%, compared to AHCO's ROE of +0.06%. Regarding short-term risk, ULGX is less volatile compared to AHCO. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, SILK has a market cap of 1.12B. Regarding current trading prices, ULGX is priced at $0.00, while SILK trades at $27.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas SILK's P/E ratio is -18.96. In terms of profitability, ULGX's ROE is +2.32%, compared to SILK's ROE of -0.37%. Regarding short-term risk, ULGX is less volatile compared to SILK. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, FNA has a market cap of 1.10B. Regarding current trading prices, ULGX is priced at $0.00, while FNA trades at $13.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas FNA's P/E ratio is -19.83. In terms of profitability, ULGX's ROE is +2.32%, compared to FNA's ROE of -0.36%. Regarding short-term risk, ULGX is less volatile compared to FNA. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, XVIPF has a market cap of 1.04B. Regarding current trading prices, ULGX is priced at $0.00, while XVIPF trades at $32.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas XVIPF's P/E ratio is 73.11. In terms of profitability, ULGX's ROE is +2.32%, compared to XVIPF's ROE of +0.07%. Regarding short-term risk, ULGX and XVIPF have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, LFTSF has a market cap of 1.03B. Regarding current trading prices, ULGX is priced at $0.00, while LFTSF trades at $0.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas LFTSF's P/E ratio is 23.35. In terms of profitability, ULGX's ROE is +2.32%, compared to LFTSF's ROE of +0.07%. Regarding short-term risk, ULGX and LFTSF have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, INMD has a market cap of 1.01B. Regarding current trading prices, ULGX is priced at $0.00, while INMD trades at $14.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas INMD's P/E ratio is 6.48. In terms of profitability, ULGX's ROE is +2.32%, compared to INMD's ROE of +0.25%. Regarding short-term risk, ULGX is less volatile compared to INMD. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, ESTA has a market cap of 980.57M. Regarding current trading prices, ULGX is priced at $0.00, while ESTA trades at $33.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas ESTA's P/E ratio is -11.31. In terms of profitability, ULGX's ROE is +2.32%, compared to ESTA's ROE of -1.80%. Regarding short-term risk, ULGX is less volatile compared to ESTA. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, IART has a market cap of 951.98M. Regarding current trading prices, ULGX is priced at $0.00, while IART trades at $12.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas IART's P/E ratio is -32.24. In terms of profitability, ULGX's ROE is +2.32%, compared to IART's ROE of -0.03%. Regarding short-term risk, ULGX is less volatile compared to IART. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, DGWPF has a market cap of 926.86M. Regarding current trading prices, ULGX is priced at $0.00, while DGWPF trades at $45.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas DGWPF's P/E ratio is 6.88. In terms of profitability, ULGX's ROE is +2.32%, compared to DGWPF's ROE of +0.09%. Regarding short-term risk, ULGX is less volatile compared to DGWPF. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, CSII has a market cap of 843.96M. Regarding current trading prices, ULGX is priced at $0.00, while CSII trades at $20.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas CSII's P/E ratio is -20.83. In terms of profitability, ULGX's ROE is +2.32%, compared to CSII's ROE of -0.14%. Regarding short-term risk, ULGX is less volatile compared to CSII. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, ELEAF has a market cap of 832.49M. Regarding current trading prices, ULGX is priced at $0.00, while ELEAF trades at $10.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas ELEAF's P/E ratio is 12.08. In terms of profitability, ULGX's ROE is +2.32%, compared to ELEAF's ROE of +0.14%. Regarding short-term risk, ULGX and ELEAF have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, MDRSF has a market cap of 826.63M. Regarding current trading prices, ULGX is priced at $0.00, while MDRSF trades at $66.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas MDRSF's P/E ratio is 196.12. In terms of profitability, ULGX's ROE is +2.32%, compared to MDRSF's ROE of +0.01%. Regarding short-term risk, ULGX is less volatile compared to MDRSF. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, CRY has a market cap of 725.15M. Regarding current trading prices, ULGX is priced at $0.00, while CRY trades at $17.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas CRY's P/E ratio is 425.71. In terms of profitability, ULGX's ROE is +2.32%, compared to CRY's ROE of -0.07%. Regarding short-term risk, ULGX is less volatile compared to CRY. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, SIBN has a market cap of 719.58M. Regarding current trading prices, ULGX is priced at $0.00, while SIBN trades at $16.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas SIBN's P/E ratio is -22.60. In terms of profitability, ULGX's ROE is +2.32%, compared to SIBN's ROE of -0.19%. Regarding short-term risk, ULGX is less volatile compared to SIBN. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, IRMD has a market cap of 659.41M. Regarding current trading prices, ULGX is priced at $0.00, while IRMD trades at $51.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas IRMD's P/E ratio is 33.46. In terms of profitability, ULGX's ROE is +2.32%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, ULGX is less volatile compared to IRMD. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, CALZF has a market cap of 650.77M. Regarding current trading prices, ULGX is priced at $0.00, while CALZF trades at $0.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas CALZF's P/E ratio is 94.20. In terms of profitability, ULGX's ROE is +2.32%, compared to CALZF's ROE of +0.07%. Regarding short-term risk, ULGX is less volatile compared to CALZF. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, AVNS has a market cap of 584.52M. Regarding current trading prices, ULGX is priced at $0.00, while AVNS trades at $12.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas AVNS's P/E ratio is -1.53. In terms of profitability, ULGX's ROE is +2.32%, compared to AVNS's ROE of -0.35%. Regarding short-term risk, ULGX is less volatile compared to AVNS. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, APEN has a market cap of 579.72M. Regarding current trading prices, ULGX is priced at $0.00, while APEN trades at $10.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas APEN's P/E ratio is -9.43. In terms of profitability, ULGX's ROE is +2.32%, compared to APEN's ROE of -0.85%. Regarding short-term risk, ULGX is less volatile compared to APEN. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, CBLL has a market cap of 572.82M. Regarding current trading prices, ULGX is priced at $0.00, while CBLL trades at $15.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas CBLL's P/E ratio is -4.71. In terms of profitability, ULGX's ROE is +2.32%, compared to CBLL's ROE of +0.88%. Regarding short-term risk, ULGX is less volatile compared to CBLL. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, BFLY-WT has a market cap of 564.62M. Regarding current trading prices, ULGX is priced at $0.00, while BFLY-WT trades at $0.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas BFLY-WT's P/E ratio is N/A. In terms of profitability, ULGX's ROE is +2.32%, compared to BFLY-WT's ROE of -0.33%. Regarding short-term risk, ULGX is less volatile compared to BFLY-WT. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, BFLY has a market cap of 550.22M. Regarding current trading prices, ULGX is priced at $0.00, while BFLY trades at $2.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas BFLY's P/E ratio is -7.42. In terms of profitability, ULGX's ROE is +2.32%, compared to BFLY's ROE of -0.33%. Regarding short-term risk, ULGX is less volatile compared to BFLY. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, KIDS has a market cap of 547.28M. Regarding current trading prices, ULGX is priced at $0.00, while KIDS trades at $22.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas KIDS's P/E ratio is -13.44. In terms of profitability, ULGX's ROE is +2.32%, compared to KIDS's ROE of -0.10%. Regarding short-term risk, ULGX is less volatile compared to KIDS. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, RXST has a market cap of 530.72M. Regarding current trading prices, ULGX is priced at $0.00, while RXST trades at $13.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas RXST's P/E ratio is -18.39. In terms of profitability, ULGX's ROE is +2.32%, compared to RXST's ROE of -0.11%. Regarding short-term risk, ULGX is less volatile compared to RXST. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, AXGN has a market cap of 517.50M. Regarding current trading prices, ULGX is priced at $0.00, while AXGN trades at $11.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas AXGN's P/E ratio is -49.41. In terms of profitability, ULGX's ROE is +2.32%, compared to AXGN's ROE of -0.10%. Regarding short-term risk, ULGX is less volatile compared to AXGN. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, AVMR has a market cap of 494.15M. Regarding current trading prices, ULGX is priced at $0.00, while AVMR trades at $9.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas AVMR's P/E ratio is -18.34. In terms of profitability, ULGX's ROE is +2.32%, compared to AVMR's ROE of -0.24%. Regarding short-term risk, ULGX and AVMR have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, OFIX has a market cap of 474.48M. Regarding current trading prices, ULGX is priced at $0.00, while OFIX trades at $12.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas OFIX's P/E ratio is -3.67. In terms of profitability, ULGX's ROE is +2.32%, compared to OFIX's ROE of -0.23%. Regarding short-term risk, ULGX is less volatile compared to OFIX. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, CLVSF has a market cap of 459.85M. Regarding current trading prices, ULGX is priced at $0.00, while CLVSF trades at $19.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas CLVSF's P/E ratio is 31.61. In terms of profitability, ULGX's ROE is +2.32%, compared to CLVSF's ROE of +0.18%. Regarding short-term risk, ULGX is less volatile compared to CLVSF. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, BVS has a market cap of 443.27M. Regarding current trading prices, ULGX is priced at $0.00, while BVS trades at $6.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas BVS's P/E ratio is -12.85. In terms of profitability, ULGX's ROE is +2.32%, compared to BVS's ROE of -0.22%. Regarding short-term risk, ULGX is less volatile compared to BVS. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, TMCI has a market cap of 428.91M. Regarding current trading prices, ULGX is priced at $0.00, while TMCI trades at $6.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas TMCI's P/E ratio is -7.58. In terms of profitability, ULGX's ROE is +2.32%, compared to TMCI's ROE of -0.49%. Regarding short-term risk, ULGX is less volatile compared to TMCI. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, NPCE has a market cap of 422.18M. Regarding current trading prices, ULGX is priced at $0.00, while NPCE trades at $12.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas NPCE's P/E ratio is -13.86. In terms of profitability, ULGX's ROE is +2.32%, compared to NPCE's ROE of -2.58%. Regarding short-term risk, ULGX is less volatile compared to NPCE. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, SENS has a market cap of 410.65M. Regarding current trading prices, ULGX is priced at $0.00, while SENS trades at $0.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas SENS's P/E ratio is -5.23. In terms of profitability, ULGX's ROE is +2.32%, compared to SENS's ROE of -5.15%. Regarding short-term risk, ULGX is less volatile compared to SENS. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, CLPT has a market cap of 394.79M. Regarding current trading prices, ULGX is priced at $0.00, while CLPT trades at $14.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas CLPT's P/E ratio is -20.16. In terms of profitability, ULGX's ROE is +2.32%, compared to CLPT's ROE of -0.62%. Regarding short-term risk, ULGX is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, SRDX has a market cap of 382.65M. Regarding current trading prices, ULGX is priced at $0.00, while SRDX trades at $26.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas SRDX's P/E ratio is -19.11. In terms of profitability, ULGX's ROE is +2.32%, compared to SRDX's ROE of -0.17%. Regarding short-term risk, ULGX is less volatile compared to SRDX. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, CTKB has a market cap of 373.23M. Regarding current trading prices, ULGX is priced at $0.00, while CTKB trades at $2.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas CTKB's P/E ratio is -58.50. In terms of profitability, ULGX's ROE is +2.32%, compared to CTKB's ROE of -0.02%. Regarding short-term risk, ULGX is less volatile compared to CTKB. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, HYBT has a market cap of 361.36M. Regarding current trading prices, ULGX is priced at $0.00, while HYBT trades at $0.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas HYBT's P/E ratio is N/A. In terms of profitability, ULGX's ROE is +2.32%, compared to HYBT's ROE of -0.02%. Regarding short-term risk, ULGX and HYBT have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, PACB has a market cap of 336.05M. Regarding current trading prices, ULGX is priced at $0.00, while PACB trades at $1.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas PACB's P/E ratio is -0.70. In terms of profitability, ULGX's ROE is +2.32%, compared to PACB's ROE of -0.59%. Regarding short-term risk, ULGX is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, NNOX has a market cap of 334.11M. Regarding current trading prices, ULGX is priced at $0.00, while NNOX trades at $5.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas NNOX's P/E ratio is -5.76. In terms of profitability, ULGX's ROE is +2.32%, compared to NNOX's ROE of -0.30%. Regarding short-term risk, ULGX is less volatile compared to NNOX. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, SMLR has a market cap of 333.86M. Regarding current trading prices, ULGX is priced at $0.00, while SMLR trades at $34.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas SMLR's P/E ratio is 6.78. In terms of profitability, ULGX's ROE is +2.32%, compared to SMLR's ROE of +0.35%. Regarding short-term risk, ULGX is less volatile compared to SMLR. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, IOBCF has a market cap of 326.64M. Regarding current trading prices, ULGX is priced at $0.00, while IOBCF trades at $11.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas IOBCF's P/E ratio is 35.97. In terms of profitability, ULGX's ROE is +2.32%, compared to IOBCF's ROE of +0.08%. Regarding short-term risk, ULGX is less volatile compared to IOBCF. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, EAPIF has a market cap of 290.45M. Regarding current trading prices, ULGX is priced at $0.00, while EAPIF trades at $3.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas EAPIF's P/E ratio is -1.96. In terms of profitability, ULGX's ROE is +2.32%, compared to EAPIF's ROE of -0.31%. Regarding short-term risk, ULGX is less volatile compared to EAPIF. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, VREX has a market cap of 283.46M. Regarding current trading prices, ULGX is priced at $0.00, while VREX trades at $6.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas VREX's P/E ratio is -5.88. In terms of profitability, ULGX's ROE is +2.32%, compared to VREX's ROE of -0.09%. Regarding short-term risk, ULGX is less volatile compared to VREX. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, OM has a market cap of 271.51M. Regarding current trading prices, ULGX is priced at $0.00, while OM trades at $15.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas OM's P/E ratio is -0.41. In terms of profitability, ULGX's ROE is +2.32%, compared to OM's ROE of -2.17%. Regarding short-term risk, ULGX is less volatile compared to OM. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, CLLKF has a market cap of 267.32M. Regarding current trading prices, ULGX is priced at $0.00, while CLLKF trades at $3.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas CLLKF's P/E ratio is -8.60. In terms of profitability, ULGX's ROE is +2.32%, compared to CLLKF's ROE of -0.12%. Regarding short-term risk, ULGX is less volatile compared to CLLKF. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, CSSPF has a market cap of 263.38M. Regarding current trading prices, ULGX is priced at $0.00, while CSSPF trades at $0.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas CSSPF's P/E ratio is 65.00. In terms of profitability, ULGX's ROE is +2.32%, compared to CSSPF's ROE of +0.16%. Regarding short-term risk, ULGX is less volatile compared to CSSPF. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, CYBQY has a market cap of 261.21M. Regarding current trading prices, ULGX is priced at $0.00, while CYBQY trades at $1.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas CYBQY's P/E ratio is -40.67. In terms of profitability, ULGX's ROE is +2.32%, compared to CYBQY's ROE of -0.02%. Regarding short-term risk, ULGX is less volatile compared to CYBQY. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, SNWV has a market cap of 257.31M. Regarding current trading prices, ULGX is priced at $0.00, while SNWV trades at $30.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas SNWV's P/E ratio is -4.28. In terms of profitability, ULGX's ROE is +2.32%, compared to SNWV's ROE of +0.78%. Regarding short-term risk, ULGX is less volatile compared to SNWV. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, MXCT has a market cap of 250.37M. Regarding current trading prices, ULGX is priced at $0.00, while MXCT trades at $2.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas MXCT's P/E ratio is -6.04. In terms of profitability, ULGX's ROE is +2.32%, compared to MXCT's ROE of -0.19%. Regarding short-term risk, ULGX is less volatile compared to MXCT. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, VMD has a market cap of 249.79M. Regarding current trading prices, ULGX is priced at $0.00, while VMD trades at $6.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas VMD's P/E ratio is 22.57. In terms of profitability, ULGX's ROE is +2.32%, compared to VMD's ROE of +0.09%. Regarding short-term risk, ULGX is less volatile compared to VMD. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, BCCOY has a market cap of 249.26M. Regarding current trading prices, ULGX is priced at $0.00, while BCCOY trades at $0.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas BCCOY's P/E ratio is -8.18. In terms of profitability, ULGX's ROE is +2.32%, compared to BCCOY's ROE of -0.12%. Regarding short-term risk, ULGX is less volatile compared to BCCOY. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, AVHHL has a market cap of 246.64M. Regarding current trading prices, ULGX is priced at $0.00, while AVHHL trades at $2.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas AVHHL's P/E ratio is -4.75. In terms of profitability, ULGX's ROE is +2.32%, compared to AVHHL's ROE of -3.38%. Regarding short-term risk, ULGX and AVHHL have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, CERS has a market cap of 246.60M. Regarding current trading prices, ULGX is priced at $0.00, while CERS trades at $1.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas CERS's P/E ratio is -12.90. In terms of profitability, ULGX's ROE is +2.32%, compared to CERS's ROE of -0.35%. Regarding short-term risk, ULGX is less volatile compared to CERS. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, HTLZF has a market cap of 245.15M. Regarding current trading prices, ULGX is priced at $0.00, while HTLZF trades at $1.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas HTLZF's P/E ratio is -159.01. In terms of profitability, ULGX's ROE is +2.32%, compared to HTLZF's ROE of -0.03%. Regarding short-term risk, ULGX and HTLZF have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, ZIMV has a market cap of 243.94M. Regarding current trading prices, ULGX is priced at $0.00, while ZIMV trades at $8.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas ZIMV's P/E ratio is -7.12. In terms of profitability, ULGX's ROE is +2.32%, compared to ZIMV's ROE of -0.07%. Regarding short-term risk, ULGX is less volatile compared to ZIMV. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, NVRO has a market cap of 224.09M. Regarding current trading prices, ULGX is priced at $0.00, while NVRO trades at $5.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas NVRO's P/E ratio is -1.91. In terms of profitability, ULGX's ROE is +2.32%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, ULGX is less volatile compared to NVRO. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, TCMD has a market cap of 221.79M. Regarding current trading prices, ULGX is priced at $0.00, while TCMD trades at $9.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas TCMD's P/E ratio is 14.45. In terms of profitability, ULGX's ROE is +2.32%, compared to TCMD's ROE of +0.08%. Regarding short-term risk, ULGX is less volatile compared to TCMD. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, EYES has a market cap of 210.05M. Regarding current trading prices, ULGX is priced at $0.00, while EYES trades at $4.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas EYES's P/E ratio is N/A. In terms of profitability, ULGX's ROE is +2.32%, compared to EYES's ROE of -0.26%. Regarding short-term risk, ULGX is less volatile compared to EYES. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, QTRX has a market cap of 204.98M. Regarding current trading prices, ULGX is priced at $0.00, while QTRX trades at $5.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas QTRX's P/E ratio is -5.28. In terms of profitability, ULGX's ROE is +2.32%, compared to QTRX's ROE of -0.12%. Regarding short-term risk, ULGX is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, MASS has a market cap of 200.86M. Regarding current trading prices, ULGX is priced at $0.00, while MASS trades at $5.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas MASS's P/E ratio is -2.65. In terms of profitability, ULGX's ROE is +2.32%, compared to MASS's ROE of -0.52%. Regarding short-term risk, ULGX is less volatile compared to MASS. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, IMPZY has a market cap of 199.95M. Regarding current trading prices, ULGX is priced at $0.00, while IMPZY trades at $0.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas IMPZY's P/E ratio is -1.60. In terms of profitability, ULGX's ROE is +2.32%, compared to IMPZY's ROE of -3.64%. Regarding short-term risk, ULGX and IMPZY have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, BDMD has a market cap of 190.37M. Regarding current trading prices, ULGX is priced at $0.00, while BDMD trades at $5.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas BDMD's P/E ratio is 15.34. In terms of profitability, ULGX's ROE is +2.32%, compared to BDMD's ROE of +0.12%. Regarding short-term risk, ULGX and BDMD have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, ELMD has a market cap of 189.92M. Regarding current trading prices, ULGX is priced at $0.00, while ELMD trades at $22.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas ELMD's P/E ratio is 29.59. In terms of profitability, ULGX's ROE is +2.32%, compared to ELMD's ROE of +0.16%. Regarding short-term risk, ULGX is less volatile compared to ELMD. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, RCEL has a market cap of 184.25M. Regarding current trading prices, ULGX is priced at $0.00, while RCEL trades at $6.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas RCEL's P/E ratio is -2.92. In terms of profitability, ULGX's ROE is +2.32%, compared to RCEL's ROE of -3.38%. Regarding short-term risk, ULGX is less volatile compared to RCEL. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, CYBQF has a market cap of 173.46M. Regarding current trading prices, ULGX is priced at $0.00, while CYBQF trades at $1.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas CYBQF's P/E ratio is -43.33. In terms of profitability, ULGX's ROE is +2.32%, compared to CYBQF's ROE of -0.02%. Regarding short-term risk, ULGX and CYBQF have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, CATX has a market cap of 172.91M. Regarding current trading prices, ULGX is priced at $0.00, while CATX trades at $2.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas CATX's P/E ratio is -1.91. In terms of profitability, ULGX's ROE is +2.32%, compared to CATX's ROE of -0.27%. Regarding short-term risk, ULGX is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, INGN has a market cap of 167.78M. Regarding current trading prices, ULGX is priced at $0.00, while INGN trades at $6.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas INGN's P/E ratio is -4.11. In terms of profitability, ULGX's ROE is +2.32%, compared to INGN's ROE of -0.19%. Regarding short-term risk, ULGX is less volatile compared to INGN. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, ANIK has a market cap of 166.93M. Regarding current trading prices, ULGX is priced at $0.00, while ANIK trades at $11.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas ANIK's P/E ratio is -19.40. In terms of profitability, ULGX's ROE is +2.32%, compared to ANIK's ROE of -0.30%. Regarding short-term risk, ULGX is less volatile compared to ANIK. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, BWAY has a market cap of 165.32M. Regarding current trading prices, ULGX is priced at $0.00, while BWAY trades at $8.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas BWAY's P/E ratio is 48.67. In terms of profitability, ULGX's ROE is +2.32%, compared to BWAY's ROE of +0.06%. Regarding short-term risk, ULGX is less volatile compared to BWAY. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, LNSR has a market cap of 164.15M. Regarding current trading prices, ULGX is priced at $0.00, while LNSR trades at $13.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas LNSR's P/E ratio is -5.10. In terms of profitability, ULGX's ROE is +2.32%, compared to LNSR's ROE of -1.14%. Regarding short-term risk, ULGX is less volatile compared to LNSR. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, EKDHF has a market cap of 162.48M. Regarding current trading prices, ULGX is priced at $0.00, while EKDHF trades at $0.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas EKDHF's P/E ratio is 18.00. In terms of profitability, ULGX's ROE is +2.32%, compared to EKDHF's ROE of +0.09%. Regarding short-term risk, ULGX is less volatile compared to EKDHF. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, TLSI has a market cap of 162.32M. Regarding current trading prices, ULGX is priced at $0.00, while TLSI trades at $5.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas TLSI's P/E ratio is -3.83. In terms of profitability, ULGX's ROE is +2.32%, compared to TLSI's ROE of +1.14%. Regarding short-term risk, ULGX is less volatile compared to TLSI. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, BRNHF has a market cap of 161.85M. Regarding current trading prices, ULGX is priced at $0.00, while BRNHF trades at $0.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas BRNHF's P/E ratio is -5.12. In terms of profitability, ULGX's ROE is +2.32%, compared to BRNHF's ROE of -0.09%. Regarding short-term risk, ULGX is less volatile compared to BRNHF. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, SGHT has a market cap of 157.67M. Regarding current trading prices, ULGX is priced at $0.00, while SGHT trades at $3.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas SGHT's P/E ratio is -2.96. In terms of profitability, ULGX's ROE is +2.32%, compared to SGHT's ROE of -0.52%. Regarding short-term risk, ULGX is less volatile compared to SGHT. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, JMDMF has a market cap of 154.98M. Regarding current trading prices, ULGX is priced at $0.00, while JMDMF trades at $5.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas JMDMF's P/E ratio is -43.25. In terms of profitability, ULGX's ROE is +2.32%, compared to JMDMF's ROE of N/A. Regarding short-term risk, ULGX is less volatile compared to JMDMF. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, PXMBF has a market cap of 154.46M. Regarding current trading prices, ULGX is priced at $0.00, while PXMBF trades at $3.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas PXMBF's P/E ratio is 29.17. In terms of profitability, ULGX's ROE is +2.32%, compared to PXMBF's ROE of +0.27%. Regarding short-term risk, ULGX and PXMBF have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, AVR has a market cap of 151.31M. Regarding current trading prices, ULGX is priced at $0.00, while AVR trades at $4.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas AVR's P/E ratio is -2.13. In terms of profitability, ULGX's ROE is +2.32%, compared to AVR's ROE of -4.16%. Regarding short-term risk, ULGX is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, PROF has a market cap of 139.08M. Regarding current trading prices, ULGX is priced at $0.00, while PROF trades at $4.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas PROF's P/E ratio is -4.13. In terms of profitability, ULGX's ROE is +2.32%, compared to PROF's ROE of -0.62%. Regarding short-term risk, ULGX is less volatile compared to PROF. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, LUNG has a market cap of 135.67M. Regarding current trading prices, ULGX is priced at $0.00, while LUNG trades at $3.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas LUNG's P/E ratio is -2.34. In terms of profitability, ULGX's ROE is +2.32%, compared to LUNG's ROE of -0.64%. Regarding short-term risk, ULGX is less volatile compared to LUNG. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, RPID has a market cap of 134.99M. Regarding current trading prices, ULGX is priced at $0.00, while RPID trades at $3.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas RPID's P/E ratio is -2.85. In terms of profitability, ULGX's ROE is +2.32%, compared to RPID's ROE of -0.52%. Regarding short-term risk, ULGX is less volatile compared to RPID. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, BRSYF has a market cap of 128.39M. Regarding current trading prices, ULGX is priced at $0.00, while BRSYF trades at $3.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas BRSYF's P/E ratio is 37.78. In terms of profitability, ULGX's ROE is +2.32%, compared to BRSYF's ROE of +0.06%. Regarding short-term risk, ULGX is less volatile compared to BRSYF. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, CVRX has a market cap of 124.29M. Regarding current trading prices, ULGX is priced at $0.00, while CVRX trades at $4.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas CVRX's P/E ratio is -1.80. In terms of profitability, ULGX's ROE is +2.32%, compared to CVRX's ROE of -0.93%. Regarding short-term risk, ULGX is less volatile compared to CVRX. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, AMEUF has a market cap of 120.50M. Regarding current trading prices, ULGX is priced at $0.00, while AMEUF trades at $5.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas AMEUF's P/E ratio is -1.75. In terms of profitability, ULGX's ROE is +2.32%, compared to AMEUF's ROE of -6.21%. Regarding short-term risk, ULGX is less volatile compared to AMEUF. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, LUCD has a market cap of 119.08M. Regarding current trading prices, ULGX is priced at $0.00, while LUCD trades at $1.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas LUCD's P/E ratio is -1.08. In terms of profitability, ULGX's ROE is +2.32%, compared to LUCD's ROE of -4.60%. Regarding short-term risk, ULGX is less volatile compared to LUCD. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, MYO has a market cap of 115.85M. Regarding current trading prices, ULGX is priced at $0.00, while MYO trades at $3.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas MYO's P/E ratio is -20.12. In terms of profitability, ULGX's ROE is +2.32%, compared to MYO's ROE of -0.45%. Regarding short-term risk, ULGX is less volatile compared to MYO. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, VMTHF has a market cap of 110.00M. Regarding current trading prices, ULGX is priced at $0.00, while VMTHF trades at $0.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas VMTHF's P/E ratio is -1.14. In terms of profitability, ULGX's ROE is +2.32%, compared to VMTHF's ROE of -0.23%. Regarding short-term risk, ULGX is less volatile compared to VMTHF. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, FDMDF has a market cap of 102.68M. Regarding current trading prices, ULGX is priced at $0.00, while FDMDF trades at $0.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas FDMDF's P/E ratio is -3.26. In terms of profitability, ULGX's ROE is +2.32%, compared to FDMDF's ROE of -0.44%. Regarding short-term risk, ULGX and FDMDF have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, ICAD has a market cap of 98.81M. Regarding current trading prices, ULGX is priced at $0.00, while ICAD trades at $3.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas ICAD's P/E ratio is -17.14. In terms of profitability, ULGX's ROE is +2.32%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, ULGX is less volatile compared to ICAD. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, HJLI has a market cap of 98.32M. Regarding current trading prices, ULGX is priced at $0.00, while HJLI trades at $10.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas HJLI's P/E ratio is N/A. In terms of profitability, ULGX's ROE is +2.32%, compared to HJLI's ROE of -0.51%. Regarding short-term risk, ULGX is less volatile compared to HJLI. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, ASXC has a market cap of 94.92M. Regarding current trading prices, ULGX is priced at $0.00, while ASXC trades at $0.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas ASXC's P/E ratio is -1.12. In terms of profitability, ULGX's ROE is +2.32%, compared to ASXC's ROE of -4.07%. Regarding short-term risk, ULGX is less volatile compared to ASXC. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, MGRM has a market cap of 94.22M. Regarding current trading prices, ULGX is priced at $0.00, while MGRM trades at $2.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas MGRM's P/E ratio is -5.24. In terms of profitability, ULGX's ROE is +2.32%, compared to MGRM's ROE of -1.29%. Regarding short-term risk, ULGX is less volatile compared to MGRM. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, QIPT has a market cap of 93.94M. Regarding current trading prices, ULGX is priced at $0.00, while QIPT trades at $2.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas QIPT's P/E ratio is -14.53. In terms of profitability, ULGX's ROE is +2.32%, compared to QIPT's ROE of -0.07%. Regarding short-term risk, ULGX is less volatile compared to QIPT. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, RSHUF has a market cap of 91.52M. Regarding current trading prices, ULGX is priced at $0.00, while RSHUF trades at $0.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas RSHUF's P/E ratio is -5.81. In terms of profitability, ULGX's ROE is +2.32%, compared to RSHUF's ROE of -2.32%. Regarding short-term risk, ULGX is less volatile compared to RSHUF. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, CKMTF has a market cap of 85.19M. Regarding current trading prices, ULGX is priced at $0.00, while CKMTF trades at $12.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas CKMTF's P/E ratio is -3.32. In terms of profitability, ULGX's ROE is +2.32%, compared to CKMTF's ROE of +2.13%. Regarding short-term risk, ULGX and CKMTF have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, SOMNF has a market cap of 84.28M. Regarding current trading prices, ULGX is priced at $0.00, while SOMNF trades at $0.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas SOMNF's P/E ratio is -13.00. In terms of profitability, ULGX's ROE is +2.32%, compared to SOMNF's ROE of -0.38%. Regarding short-term risk, ULGX is less volatile compared to SOMNF. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, EDAP has a market cap of 83.01M. Regarding current trading prices, ULGX is priced at $0.00, while EDAP trades at $2.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas EDAP's P/E ratio is -3.83. In terms of profitability, ULGX's ROE is +2.32%, compared to EDAP's ROE of -0.41%. Regarding short-term risk, ULGX is less volatile compared to EDAP. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, NVCN has a market cap of 82.86M. Regarding current trading prices, ULGX is priced at $0.00, while NVCN trades at $30.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas NVCN's P/E ratio is -1.99. In terms of profitability, ULGX's ROE is +2.32%, compared to NVCN's ROE of -1.21%. Regarding short-term risk, ULGX is less volatile compared to NVCN. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, OWLT has a market cap of 80.45M. Regarding current trading prices, ULGX is priced at $0.00, while OWLT trades at $4.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas OWLT's P/E ratio is -3.09. In terms of profitability, ULGX's ROE is +2.32%, compared to OWLT's ROE of +0.65%. Regarding short-term risk, ULGX is less volatile compared to OWLT. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, NSPR has a market cap of 79.65M. Regarding current trading prices, ULGX is priced at $0.00, while NSPR trades at $2.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas NSPR's P/E ratio is -3.42. In terms of profitability, ULGX's ROE is +2.32%, compared to NSPR's ROE of -0.80%. Regarding short-term risk, ULGX is less volatile compared to NSPR. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, FONR has a market cap of 77.89M. Regarding current trading prices, ULGX is priced at $0.00, while FONR trades at $12.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas FONR's P/E ratio is 10.90. In terms of profitability, ULGX's ROE is +2.32%, compared to FONR's ROE of +0.05%. Regarding short-term risk, ULGX is less volatile compared to FONR. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, DMTRF has a market cap of 76.10M. Regarding current trading prices, ULGX is priced at $0.00, while DMTRF trades at $0.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas DMTRF's P/E ratio is -9.86. In terms of profitability, ULGX's ROE is +2.32%, compared to DMTRF's ROE of -0.24%. Regarding short-term risk, ULGX is less volatile compared to DMTRF. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, IPDQF has a market cap of 75.83M. Regarding current trading prices, ULGX is priced at $0.00, while IPDQF trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas IPDQF's P/E ratio is -3.74. In terms of profitability, ULGX's ROE is +2.32%, compared to IPDQF's ROE of -0.43%. Regarding short-term risk, ULGX is less volatile compared to IPDQF. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, RSLS has a market cap of 75.10M. Regarding current trading prices, ULGX is priced at $0.00, while RSLS trades at $6.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas RSLS's P/E ratio is -0.48. In terms of profitability, ULGX's ROE is +2.32%, compared to RSLS's ROE of -3.24%. Regarding short-term risk, ULGX is less volatile compared to RSLS. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, SRTS has a market cap of 74.06M. Regarding current trading prices, ULGX is priced at $0.00, while SRTS trades at $4.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas SRTS's P/E ratio is 10.95. In terms of profitability, ULGX's ROE is +2.32%, compared to SRTS's ROE of +0.12%. Regarding short-term risk, ULGX is less volatile compared to SRTS. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, SNZZF has a market cap of 71.91M. Regarding current trading prices, ULGX is priced at $0.00, while SNZZF trades at $0.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas SNZZF's P/E ratio is -5.40. In terms of profitability, ULGX's ROE is +2.32%, compared to SNZZF's ROE of -0.40%. Regarding short-term risk, ULGX is less volatile compared to SNZZF. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, XTNT has a market cap of 70.83M. Regarding current trading prices, ULGX is priced at $0.00, while XTNT trades at $0.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas XTNT's P/E ratio is -4.24. In terms of profitability, ULGX's ROE is +2.32%, compared to XTNT's ROE of -0.36%. Regarding short-term risk, ULGX is less volatile compared to XTNT. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, NVNO has a market cap of 64.01M. Regarding current trading prices, ULGX is priced at $0.00, while NVNO trades at $3.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas NVNO's P/E ratio is -3.09. In terms of profitability, ULGX's ROE is +2.32%, compared to NVNO's ROE of -0.51%. Regarding short-term risk, ULGX is less volatile compared to NVNO. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, RWLK has a market cap of 63.03M. Regarding current trading prices, ULGX is priced at $0.00, while RWLK trades at $1.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas RWLK's P/E ratio is -2.92. In terms of profitability, ULGX's ROE is +2.32%, compared to RWLK's ROE of -0.89%. Regarding short-term risk, ULGX is less volatile compared to RWLK. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, PTHL has a market cap of 62.61M. Regarding current trading prices, ULGX is priced at $0.00, while PTHL trades at $4.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas PTHL's P/E ratio is -87.88. In terms of profitability, ULGX's ROE is +2.32%, compared to PTHL's ROE of N/A. Regarding short-term risk, ULGX is less volatile compared to PTHL. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, NVNOW has a market cap of 62.60M. Regarding current trading prices, ULGX is priced at $0.00, while NVNOW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas NVNOW's P/E ratio is -0.00. In terms of profitability, ULGX's ROE is +2.32%, compared to NVNOW's ROE of -0.51%. Regarding short-term risk, ULGX is less volatile compared to NVNOW. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, VANI has a market cap of 61.32M. Regarding current trading prices, ULGX is priced at $0.00, while VANI trades at $1.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas VANI's P/E ratio is -2.41. In terms of profitability, ULGX's ROE is +2.32%, compared to VANI's ROE of -1.06%. Regarding short-term risk, ULGX and VANI have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, RDGL has a market cap of 60.63M. Regarding current trading prices, ULGX is priced at $0.00, while RDGL trades at $0.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas RDGL's P/E ratio is -13.37. In terms of profitability, ULGX's ROE is +2.32%, compared to RDGL's ROE of -1.86%. Regarding short-term risk, ULGX is less volatile compared to RDGL. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, ICCM has a market cap of 58.27M. Regarding current trading prices, ULGX is priced at $0.00, while ICCM trades at $1.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas ICCM's P/E ratio is -3.43. In terms of profitability, ULGX's ROE is +2.32%, compared to ICCM's ROE of -1.56%. Regarding short-term risk, ULGX is less volatile compared to ICCM. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, HYPR has a market cap of 57.93M. Regarding current trading prices, ULGX is priced at $0.00, while HYPR trades at $0.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas HYPR's P/E ratio is -1.33. In terms of profitability, ULGX's ROE is +2.32%, compared to HYPR's ROE of -0.65%. Regarding short-term risk, ULGX is less volatile compared to HYPR. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, CTSO has a market cap of 54.53M. Regarding current trading prices, ULGX is priced at $0.00, while CTSO trades at $0.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas CTSO's P/E ratio is -2.29. In terms of profitability, ULGX's ROE is +2.32%, compared to CTSO's ROE of -1.39%. Regarding short-term risk, ULGX is less volatile compared to CTSO. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, RBOT-WT has a market cap of 54.23M. Regarding current trading prices, ULGX is priced at $0.00, while RBOT-WT trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas RBOT-WT's P/E ratio is N/A. In terms of profitability, ULGX's ROE is +2.32%, compared to RBOT-WT's ROE of -0.97%. Regarding short-term risk, ULGX is less volatile compared to RBOT-WT. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, MODD has a market cap of 53.71M. Regarding current trading prices, ULGX is priced at $0.00, while MODD trades at $1.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas MODD's P/E ratio is -1.89. In terms of profitability, ULGX's ROE is +2.32%, compared to MODD's ROE of -1.98%. Regarding short-term risk, ULGX is less volatile compared to MODD. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, EAR has a market cap of 53.36M. Regarding current trading prices, ULGX is priced at $0.00, while EAR trades at $2.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas EAR's P/E ratio is 0.17. In terms of profitability, ULGX's ROE is +2.32%, compared to EAR's ROE of -0.81%. Regarding short-term risk, ULGX is less volatile compared to EAR. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, RBOT has a market cap of 51.81M. Regarding current trading prices, ULGX is priced at $0.00, while RBOT trades at $8.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas RBOT's P/E ratio is -0.81. In terms of profitability, ULGX's ROE is +2.32%, compared to RBOT's ROE of -0.97%. Regarding short-term risk, ULGX is less volatile compared to RBOT. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, BLOZF has a market cap of 48.36M. Regarding current trading prices, ULGX is priced at $0.00, while BLOZF trades at $0.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas BLOZF's P/E ratio is -21.00. In terms of profitability, ULGX's ROE is +2.32%, compared to BLOZF's ROE of -0.89%. Regarding short-term risk, ULGX is less volatile compared to BLOZF. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, BSGM has a market cap of 47.05M. Regarding current trading prices, ULGX is priced at $0.00, while BSGM trades at $1.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas BSGM's P/E ratio is -2.59. In terms of profitability, ULGX's ROE is +2.32%, compared to BSGM's ROE of +7.10%. Regarding short-term risk, ULGX is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, APYX has a market cap of 43.84M. Regarding current trading prices, ULGX is priced at $0.00, while APYX trades at $1.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas APYX's P/E ratio is -1.76. In terms of profitability, ULGX's ROE is +2.32%, compared to APYX's ROE of -1.56%. Regarding short-term risk, ULGX is less volatile compared to APYX. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, TELA has a market cap of 42.72M. Regarding current trading prices, ULGX is priced at $0.00, while TELA trades at $1.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas TELA's P/E ratio is -0.81. In terms of profitability, ULGX's ROE is +2.32%, compared to TELA's ROE of -3.84%. Regarding short-term risk, ULGX is less volatile compared to TELA. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, DNAY has a market cap of 38.32M. Regarding current trading prices, ULGX is priced at $0.00, while DNAY trades at $1.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas DNAY's P/E ratio is N/A. In terms of profitability, ULGX's ROE is +2.32%, compared to DNAY's ROE of -0.86%. Regarding short-term risk, ULGX is less volatile compared to DNAY. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, NVYTF has a market cap of 38.00M. Regarding current trading prices, ULGX is priced at $0.00, while NVYTF trades at $0.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas NVYTF's P/E ratio is -0.78. In terms of profitability, ULGX's ROE is +2.32%, compared to NVYTF's ROE of -0.23%. Regarding short-term risk, ULGX is less volatile compared to NVYTF. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, COCH has a market cap of 36.04M. Regarding current trading prices, ULGX is priced at $0.00, while COCH trades at $1.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas COCH's P/E ratio is -1.23. In terms of profitability, ULGX's ROE is +2.32%, compared to COCH's ROE of +1.06%. Regarding short-term risk, ULGX is less volatile compared to COCH. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, ECOR has a market cap of 34.51M. Regarding current trading prices, ULGX is priced at $0.00, while ECOR trades at $4.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas ECOR's P/E ratio is -2.92. In terms of profitability, ULGX's ROE is +2.32%, compared to ECOR's ROE of -1.44%. Regarding short-term risk, ULGX is less volatile compared to ECOR. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, TLTFF has a market cap of 34.39M. Regarding current trading prices, ULGX is priced at $0.00, while TLTFF trades at $0.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas TLTFF's P/E ratio is -13.88. In terms of profitability, ULGX's ROE is +2.32%, compared to TLTFF's ROE of -2.17%. Regarding short-term risk, ULGX is less volatile compared to TLTFF. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, MDAI has a market cap of 31.93M. Regarding current trading prices, ULGX is priced at $0.00, while MDAI trades at $1.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas MDAI's P/E ratio is -1.46. In terms of profitability, ULGX's ROE is +2.32%, compared to MDAI's ROE of +3.43%. Regarding short-term risk, ULGX is less volatile compared to MDAI. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, ISO has a market cap of 30.28M. Regarding current trading prices, ULGX is priced at $0.00, while ISO trades at $0.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas ISO's P/E ratio is -0.30. In terms of profitability, ULGX's ROE is +2.32%, compared to ISO's ROE of -1.26%. Regarding short-term risk, ULGX is less volatile compared to ISO. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, NMTC has a market cap of 29.62M. Regarding current trading prices, ULGX is priced at $0.00, while NMTC trades at $0.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas NMTC's P/E ratio is -2.40. In terms of profitability, ULGX's ROE is +2.32%, compared to NMTC's ROE of -2.71%. Regarding short-term risk, ULGX is less volatile compared to NMTC. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, ELXMF has a market cap of 28.41M. Regarding current trading prices, ULGX is priced at $0.00, while ELXMF trades at $0.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas ELXMF's P/E ratio is -2.00. In terms of profitability, ULGX's ROE is +2.32%, compared to ELXMF's ROE of -0.46%. Regarding short-term risk, ULGX and ELXMF have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, PYNKF has a market cap of 24.82M. Regarding current trading prices, ULGX is priced at $0.00, while PYNKF trades at $0.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas PYNKF's P/E ratio is -1.48. In terms of profitability, ULGX's ROE is +2.32%, compared to PYNKF's ROE of -1.17%. Regarding short-term risk, ULGX is less volatile compared to PYNKF. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, AZYO has a market cap of 24.21M. Regarding current trading prices, ULGX is priced at $0.00, while AZYO trades at $1.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas AZYO's P/E ratio is -0.68. In terms of profitability, ULGX's ROE is +2.32%, compared to AZYO's ROE of +0.79%. Regarding short-term risk, ULGX is less volatile compared to AZYO. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, KBBTF has a market cap of 24.10M. Regarding current trading prices, ULGX is priced at $0.00, while KBBTF trades at $0.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas KBBTF's P/E ratio is -2.30. In terms of profitability, ULGX's ROE is +2.32%, compared to KBBTF's ROE of N/A. Regarding short-term risk, ULGX and KBBTF have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, ADGM has a market cap of 22.46M. Regarding current trading prices, ULGX is priced at $0.00, while ADGM trades at $1.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas ADGM's P/E ratio is -0.53. In terms of profitability, ULGX's ROE is +2.32%, compared to ADGM's ROE of -1.81%. Regarding short-term risk, ULGX is less volatile compared to ADGM. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, EMITF has a market cap of 22.19M. Regarding current trading prices, ULGX is priced at $0.00, while EMITF trades at $2.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas EMITF's P/E ratio is -14.29. In terms of profitability, ULGX's ROE is +2.32%, compared to EMITF's ROE of +0.05%. Regarding short-term risk, ULGX is less volatile compared to EMITF. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, POSC has a market cap of 20.84M. Regarding current trading prices, ULGX is priced at $0.00, while POSC trades at $1.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas POSC's P/E ratio is 0.35. In terms of profitability, ULGX's ROE is +2.32%, compared to POSC's ROE of +9.25%. Regarding short-term risk, ULGX is less volatile compared to POSC. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, NXLIW has a market cap of 20.21M. Regarding current trading prices, ULGX is priced at $0.00, while NXLIW trades at $0.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas NXLIW's P/E ratio is N/A. In terms of profitability, ULGX's ROE is +2.32%, compared to NXLIW's ROE of -2.47%. Regarding short-term risk, ULGX is less volatile compared to NXLIW. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, IRIX has a market cap of 19.39M. Regarding current trading prices, ULGX is priced at $0.00, while IRIX trades at $1.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas IRIX's P/E ratio is -2.14. In terms of profitability, ULGX's ROE is +2.32%, compared to IRIX's ROE of -2.31%. Regarding short-term risk, ULGX is less volatile compared to IRIX. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, LHDX has a market cap of 18.36M. Regarding current trading prices, ULGX is priced at $0.00, while LHDX trades at $0.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas LHDX's P/E ratio is -0.14. In terms of profitability, ULGX's ROE is +2.32%, compared to LHDX's ROE of -1.02%. Regarding short-term risk, ULGX is less volatile compared to LHDX. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, CFMS has a market cap of 17.88M. Regarding current trading prices, ULGX is priced at $0.00, while CFMS trades at $2.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas CFMS's P/E ratio is -0.40. In terms of profitability, ULGX's ROE is +2.32%, compared to CFMS's ROE of -0.65%. Regarding short-term risk, ULGX is less volatile compared to CFMS. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, VVOS has a market cap of 17.66M. Regarding current trading prices, ULGX is priced at $0.00, while VVOS trades at $3.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas VVOS's P/E ratio is -1.35. In terms of profitability, ULGX's ROE is +2.32%, compared to VVOS's ROE of -1.98%. Regarding short-term risk, ULGX is less volatile compared to VVOS. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, ALUR has a market cap of 17.37M. Regarding current trading prices, ULGX is priced at $0.00, while ALUR trades at $2.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas ALUR's P/E ratio is -0.20. In terms of profitability, ULGX's ROE is +2.32%, compared to ALUR's ROE of +0.38%. Regarding short-term risk, ULGX is less volatile compared to ALUR. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, XAIR has a market cap of 16.94M. Regarding current trading prices, ULGX is priced at $0.00, while XAIR trades at $0.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas XAIR's P/E ratio is -0.20. In terms of profitability, ULGX's ROE is +2.32%, compared to XAIR's ROE of -2.41%. Regarding short-term risk, ULGX is less volatile compared to XAIR. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, NXL has a market cap of 16.93M. Regarding current trading prices, ULGX is priced at $0.00, while NXL trades at $1.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas NXL's P/E ratio is -1.53. In terms of profitability, ULGX's ROE is +2.32%, compared to NXL's ROE of -2.47%. Regarding short-term risk, ULGX is less volatile compared to NXL. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, ASAPF has a market cap of 16.41M. Regarding current trading prices, ULGX is priced at $0.00, while ASAPF trades at $0.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas ASAPF's P/E ratio is -21.25. In terms of profitability, ULGX's ROE is +2.32%, compared to ASAPF's ROE of -0.20%. Regarding short-term risk, ULGX is less volatile compared to ASAPF. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, TMDI has a market cap of 15.66M. Regarding current trading prices, ULGX is priced at $0.00, while TMDI trades at $0.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas TMDI's P/E ratio is -0.88. In terms of profitability, ULGX's ROE is +2.32%, compared to TMDI's ROE of -1.38%. Regarding short-term risk, ULGX is less volatile compared to TMDI. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, MDXHF has a market cap of 15.49M. Regarding current trading prices, ULGX is priced at $0.00, while MDXHF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas MDXHF's P/E ratio is -0.08. In terms of profitability, ULGX's ROE is +2.32%, compared to MDXHF's ROE of +0.39%. Regarding short-term risk, ULGX and MDXHF have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, VPTDF has a market cap of 15.26M. Regarding current trading prices, ULGX is priced at $0.00, while VPTDF trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas VPTDF's P/E ratio is -4.68. In terms of profitability, ULGX's ROE is +2.32%, compared to VPTDF's ROE of +3.89%. Regarding short-term risk, ULGX is less volatile compared to VPTDF. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, PETV has a market cap of 14.84M. Regarding current trading prices, ULGX is priced at $0.00, while PETV trades at $0.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas PETV's P/E ratio is -1.43. In terms of profitability, ULGX's ROE is +2.32%, compared to PETV's ROE of -28.07%. Regarding short-term risk, ULGX is less volatile compared to PETV. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, LFWD has a market cap of 14.56M. Regarding current trading prices, ULGX is priced at $0.00, while LFWD trades at $1.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas LFWD's P/E ratio is -0.41. In terms of profitability, ULGX's ROE is +2.32%, compared to LFWD's ROE of -0.89%. Regarding short-term risk, ULGX is less volatile compared to LFWD. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, IINN has a market cap of 14.35M. Regarding current trading prices, ULGX is priced at $0.00, while IINN trades at $0.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas IINN's P/E ratio is -0.93. In terms of profitability, ULGX's ROE is +2.32%, compared to IINN's ROE of -0.00%. Regarding short-term risk, ULGX is less volatile compared to IINN. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, TMDIF has a market cap of 13.91M. Regarding current trading prices, ULGX is priced at $0.00, while TMDIF trades at $0.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas TMDIF's P/E ratio is -0.65. In terms of profitability, ULGX's ROE is +2.32%, compared to TMDIF's ROE of -1.06%. Regarding short-term risk, ULGX is less volatile compared to TMDIF. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, DIZTF has a market cap of 13.69M. Regarding current trading prices, ULGX is priced at $0.00, while DIZTF trades at $0.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas DIZTF's P/E ratio is -5.67. In terms of profitability, ULGX's ROE is +2.32%, compared to DIZTF's ROE of -2.82%. Regarding short-term risk, ULGX is less volatile compared to DIZTF. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, VAPO has a market cap of 13.55M. Regarding current trading prices, ULGX is priced at $0.00, while VAPO trades at $2.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas VAPO's P/E ratio is -0.26. In terms of profitability, ULGX's ROE is +2.32%, compared to VAPO's ROE of +0.86%. Regarding short-term risk, ULGX and VAPO have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, PLLWF has a market cap of 13.28M. Regarding current trading prices, ULGX is priced at $0.00, while PLLWF trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas PLLWF's P/E ratio is -0.37. In terms of profitability, ULGX's ROE is +2.32%, compared to PLLWF's ROE of -0.65%. Regarding short-term risk, ULGX is less volatile compared to PLLWF. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, RMSL has a market cap of 12.74M. Regarding current trading prices, ULGX is priced at $0.00, while RMSL trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas RMSL's P/E ratio is 0.83. In terms of profitability, ULGX's ROE is +2.32%, compared to RMSL's ROE of -1.94%. Regarding short-term risk, ULGX is less volatile compared to RMSL. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, BTCY has a market cap of 12.62M. Regarding current trading prices, ULGX is priced at $0.00, while BTCY trades at $0.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas BTCY's P/E ratio is -0.32. In terms of profitability, ULGX's ROE is +2.32%, compared to BTCY's ROE of +0.37%. Regarding short-term risk, ULGX and BTCY have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, PAVM has a market cap of 11.84M. Regarding current trading prices, ULGX is priced at $0.00, while PAVM trades at $0.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas PAVM's P/E ratio is 1.36. In terms of profitability, ULGX's ROE is +2.32%, compared to PAVM's ROE of -1.06%. Regarding short-term risk, ULGX is less volatile compared to PAVM. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, IMEXF has a market cap of 11.74M. Regarding current trading prices, ULGX is priced at $0.00, while IMEXF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas IMEXF's P/E ratio is N/A. In terms of profitability, ULGX's ROE is +2.32%, compared to IMEXF's ROE of +0.20%. Regarding short-term risk, ULGX is less volatile compared to IMEXF. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, NGMDF has a market cap of 11.51M. Regarding current trading prices, ULGX is priced at $0.00, while NGMDF trades at $0.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas NGMDF's P/E ratio is -1.83. In terms of profitability, ULGX's ROE is +2.32%, compared to NGMDF's ROE of +2.16%. Regarding short-term risk, ULGX is less volatile compared to NGMDF. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, ATBPF has a market cap of 11.43M. Regarding current trading prices, ULGX is priced at $0.00, while ATBPF trades at $0.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas ATBPF's P/E ratio is -0.86. In terms of profitability, ULGX's ROE is +2.32%, compared to ATBPF's ROE of -0.40%. Regarding short-term risk, ULGX is less volatile compared to ATBPF. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, CODX has a market cap of 11.41M. Regarding current trading prices, ULGX is priced at $0.00, while CODX trades at $0.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas CODX's P/E ratio is -0.27. In terms of profitability, ULGX's ROE is +2.32%, compared to CODX's ROE of -0.56%. Regarding short-term risk, ULGX is less volatile compared to CODX. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, LXXGF has a market cap of 11.34M. Regarding current trading prices, ULGX is priced at $0.00, while LXXGF trades at $0.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas LXXGF's P/E ratio is -0.85. In terms of profitability, ULGX's ROE is +2.32%, compared to LXXGF's ROE of -1.23%. Regarding short-term risk, ULGX and LXXGF have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, QTI has a market cap of 10.72M. Regarding current trading prices, ULGX is priced at $0.00, while QTI trades at $0.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas QTI's P/E ratio is -0.99. In terms of profitability, ULGX's ROE is +2.32%, compared to QTI's ROE of +6.04%. Regarding short-term risk, ULGX is less volatile compared to QTI. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, SSKN has a market cap of 10.26M. Regarding current trading prices, ULGX is priced at $0.00, while SSKN trades at $2.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas SSKN's P/E ratio is -0.93. In terms of profitability, ULGX's ROE is +2.32%, compared to SSKN's ROE of -1.21%. Regarding short-term risk, ULGX is less volatile compared to SSKN. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, NURO has a market cap of 9.43M. Regarding current trading prices, ULGX is priced at $0.00, while NURO trades at $4.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas NURO's P/E ratio is -1.16. In terms of profitability, ULGX's ROE is +2.32%, compared to NURO's ROE of -0.47%. Regarding short-term risk, ULGX is less volatile compared to NURO. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, BMRA has a market cap of 9.11M. Regarding current trading prices, ULGX is priced at $0.00, while BMRA trades at $3.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas BMRA's P/E ratio is -1.66. In terms of profitability, ULGX's ROE is +2.32%, compared to BMRA's ROE of -0.86%. Regarding short-term risk, ULGX is less volatile compared to BMRA. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, DHAI has a market cap of 8.57M. Regarding current trading prices, ULGX is priced at $0.00, while DHAI trades at $0.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas DHAI's P/E ratio is -0.57. In terms of profitability, ULGX's ROE is +2.32%, compared to DHAI's ROE of +0.26%. Regarding short-term risk, ULGX is less volatile compared to DHAI. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, OSA has a market cap of 8.18M. Regarding current trading prices, ULGX is priced at $0.00, while OSA trades at $0.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas OSA's P/E ratio is -0.32. In terms of profitability, ULGX's ROE is +2.32%, compared to OSA's ROE of +0.57%. Regarding short-term risk, ULGX is less volatile compared to OSA. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, GTHP has a market cap of 7.80M. Regarding current trading prices, ULGX is priced at $0.00, while GTHP trades at $0.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas GTHP's P/E ratio is -2.00. In terms of profitability, ULGX's ROE is +2.32%, compared to GTHP's ROE of +0.56%. Regarding short-term risk, ULGX and GTHP have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, TBRIF has a market cap of 7.25M. Regarding current trading prices, ULGX is priced at $0.00, while TBRIF trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas TBRIF's P/E ratio is -1.59. In terms of profitability, ULGX's ROE is +2.32%, compared to TBRIF's ROE of -2.22%. Regarding short-term risk, ULGX is less volatile compared to TBRIF. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, TNON has a market cap of 7.01M. Regarding current trading prices, ULGX is priced at $0.00, while TNON trades at $1.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas TNON's P/E ratio is -0.10. In terms of profitability, ULGX's ROE is +2.32%, compared to TNON's ROE of -2.94%. Regarding short-term risk, ULGX is less volatile compared to TNON. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, MKEAF has a market cap of 6.46M. Regarding current trading prices, ULGX is priced at $0.00, while MKEAF trades at $0.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas MKEAF's P/E ratio is -4.11. In terms of profitability, ULGX's ROE is +2.32%, compared to MKEAF's ROE of +0.60%. Regarding short-term risk, ULGX and MKEAF have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, AEMD has a market cap of 5.89M. Regarding current trading prices, ULGX is priced at $0.00, while AEMD trades at $0.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas AEMD's P/E ratio is -0.24. In terms of profitability, ULGX's ROE is +2.32%, compared to AEMD's ROE of -0.01%. Regarding short-term risk, ULGX is less volatile compared to AEMD. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, IRME has a market cap of 5.88M. Regarding current trading prices, ULGX is priced at $0.00, while IRME trades at $0.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas IRME's P/E ratio is -2.72. In terms of profitability, ULGX's ROE is +2.32%, compared to IRME's ROE of +506.40%. Regarding short-term risk, ULGX is less volatile compared to IRME. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, DTXMF has a market cap of 5.69M. Regarding current trading prices, ULGX is priced at $0.00, while DTXMF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas DTXMF's P/E ratio is -0.30. In terms of profitability, ULGX's ROE is +2.32%, compared to DTXMF's ROE of -0.41%. Regarding short-term risk, ULGX is less volatile compared to DTXMF. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, MOVE has a market cap of 5.59M. Regarding current trading prices, ULGX is priced at $0.00, while MOVE trades at $0.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas MOVE's P/E ratio is -0.20. In terms of profitability, ULGX's ROE is +2.32%, compared to MOVE's ROE of -2.88%. Regarding short-term risk, ULGX is less volatile compared to MOVE. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, OBLN has a market cap of 5.47M. Regarding current trading prices, ULGX is priced at $0.00, while OBLN trades at $3.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas OBLN's P/E ratio is -2.22. In terms of profitability, ULGX's ROE is +2.32%, compared to OBLN's ROE of -1.20%. Regarding short-term risk, ULGX is less volatile compared to OBLN. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, QLIS has a market cap of 5.45M. Regarding current trading prices, ULGX is priced at $0.00, while QLIS trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas QLIS's P/E ratio is 2.22. In terms of profitability, ULGX's ROE is +2.32%, compared to QLIS's ROE of -8.21%. Regarding short-term risk, ULGX and QLIS have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, RHNMF has a market cap of 5.45M. Regarding current trading prices, ULGX is priced at $0.00, while RHNMF trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas RHNMF's P/E ratio is -0.95. In terms of profitability, ULGX's ROE is +2.32%, compared to RHNMF's ROE of -2.48%. Regarding short-term risk, ULGX is less volatile compared to RHNMF. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, IINNW has a market cap of 5.12M. Regarding current trading prices, ULGX is priced at $0.00, while IINNW trades at $0.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas IINNW's P/E ratio is -0.05. In terms of profitability, ULGX's ROE is +2.32%, compared to IINNW's ROE of -0.00%. Regarding short-term risk, ULGX and IINNW have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, VYCO has a market cap of 5.06M. Regarding current trading prices, ULGX is priced at $0.00, while VYCO trades at $0.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas VYCO's P/E ratio is -15.17. In terms of profitability, ULGX's ROE is +2.32%, compared to VYCO's ROE of +0.03%. Regarding short-term risk, ULGX and VYCO have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, ADMT has a market cap of 4.73M. Regarding current trading prices, ULGX is priced at $0.00, while ADMT trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas ADMT's P/E ratio is -7.00. In terms of profitability, ULGX's ROE is +2.32%, compared to ADMT's ROE of -0.63%. Regarding short-term risk, ULGX is less volatile compared to ADMT. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, MICR has a market cap of 4.73M. Regarding current trading prices, ULGX is priced at $0.00, while MICR trades at $1.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas MICR's P/E ratio is -3.47. In terms of profitability, ULGX's ROE is +2.32%, compared to MICR's ROE of -0.25%. Regarding short-term risk, ULGX is less volatile compared to MICR. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, VRAY has a market cap of 4.56M. Regarding current trading prices, ULGX is priced at $0.00, while VRAY trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas VRAY's P/E ratio is -0.10. In terms of profitability, ULGX's ROE is +2.32%, compared to VRAY's ROE of -0.85%. Regarding short-term risk, ULGX is less volatile compared to VRAY. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, SINT has a market cap of 4.47M. Regarding current trading prices, ULGX is priced at $0.00, while SINT trades at $3.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas SINT's P/E ratio is -0.03. In terms of profitability, ULGX's ROE is +2.32%, compared to SINT's ROE of -1.56%. Regarding short-term risk, ULGX is less volatile compared to SINT. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, MDGS has a market cap of 4.47M. Regarding current trading prices, ULGX is priced at $0.00, while MDGS trades at $2.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas MDGS's P/E ratio is -0.27. In terms of profitability, ULGX's ROE is +2.32%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, ULGX is less volatile compared to MDGS. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, FZMD has a market cap of 4.43M. Regarding current trading prices, ULGX is priced at $0.00, while FZMD trades at $0.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas FZMD's P/E ratio is 1.20. In terms of profitability, ULGX's ROE is +2.32%, compared to FZMD's ROE of +0.13%. Regarding short-term risk, ULGX is less volatile compared to FZMD. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, AMIX has a market cap of 4.38M. Regarding current trading prices, ULGX is priced at $0.00, while AMIX trades at $1.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas AMIX's P/E ratio is -0.10. In terms of profitability, ULGX's ROE is +2.32%, compared to AMIX's ROE of -2.12%. Regarding short-term risk, ULGX is less volatile compared to AMIX. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, NUWE has a market cap of 4.29M. Regarding current trading prices, ULGX is priced at $0.00, while NUWE trades at $0.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas NUWE's P/E ratio is -0.12. In terms of profitability, ULGX's ROE is +2.32%, compared to NUWE's ROE of -11.30%. Regarding short-term risk, ULGX and NUWE have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, NUMD has a market cap of 4.18M. Regarding current trading prices, ULGX is priced at $0.00, while NUMD trades at $0.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas NUMD's P/E ratio is 5.00. In terms of profitability, ULGX's ROE is +2.32%, compared to NUMD's ROE of +0.35%. Regarding short-term risk, ULGX is less volatile compared to NUMD. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, LBLTF has a market cap of 4.07M. Regarding current trading prices, ULGX is priced at $0.00, while LBLTF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas LBLTF's P/E ratio is -0.01. In terms of profitability, ULGX's ROE is +2.32%, compared to LBLTF's ROE of +0.00%. Regarding short-term risk, ULGX is less volatile compared to LBLTF. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, XYLO has a market cap of 3.89M. Regarding current trading prices, ULGX is priced at $0.00, while XYLO trades at $5.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas XYLO's P/E ratio is -0.65. In terms of profitability, ULGX's ROE is +2.32%, compared to XYLO's ROE of -0.67%. Regarding short-term risk, ULGX is less volatile compared to XYLO. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, RMED has a market cap of 3.84M. Regarding current trading prices, ULGX is priced at $0.00, while RMED trades at $0.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas RMED's P/E ratio is -0.02. In terms of profitability, ULGX's ROE is +2.32%, compared to RMED's ROE of -0.15%. Regarding short-term risk, ULGX is less volatile compared to RMED. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, AXDX has a market cap of 3.73M. Regarding current trading prices, ULGX is priced at $0.00, while AXDX trades at $0.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas AXDX's P/E ratio is -0.07. In terms of profitability, ULGX's ROE is +2.32%, compared to AXDX's ROE of +1.21%. Regarding short-term risk, ULGX is less volatile compared to AXDX. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, HSCS has a market cap of 3.71M. Regarding current trading prices, ULGX is priced at $0.00, while HSCS trades at $3.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas HSCS's P/E ratio is -0.45. In terms of profitability, ULGX's ROE is +2.32%, compared to HSCS's ROE of -1.75%. Regarding short-term risk, ULGX is less volatile compared to HSCS. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, BIEL has a market cap of 3.62M. Regarding current trading prices, ULGX is priced at $0.00, while BIEL trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas BIEL's P/E ratio is N/A. In terms of profitability, ULGX's ROE is +2.32%, compared to BIEL's ROE of +0.04%. Regarding short-term risk, ULGX and BIEL have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, VERO has a market cap of 3.46M. Regarding current trading prices, ULGX is priced at $0.00, while VERO trades at $2.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas VERO's P/E ratio is -0.03. In terms of profitability, ULGX's ROE is +2.32%, compared to VERO's ROE of +29.81%. Regarding short-term risk, ULGX is less volatile compared to VERO. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, NAOV has a market cap of 3.40M. Regarding current trading prices, ULGX is priced at $0.00, while NAOV trades at $4.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas NAOV's P/E ratio is -0.03. In terms of profitability, ULGX's ROE is +2.32%, compared to NAOV's ROE of -1.68%. Regarding short-term risk, ULGX is less volatile compared to NAOV. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, VANIW has a market cap of 3.36M. Regarding current trading prices, ULGX is priced at $0.00, while VANIW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas VANIW's P/E ratio is N/A. In terms of profitability, ULGX's ROE is +2.32%, compared to VANIW's ROE of -1.06%. Regarding short-term risk, ULGX is less volatile compared to VANIW. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, INVO has a market cap of 3.25M. Regarding current trading prices, ULGX is priced at $0.00, while INVO trades at $0.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas INVO's P/E ratio is 1.21. In terms of profitability, ULGX's ROE is +2.32%, compared to INVO's ROE of -10.74%. Regarding short-term risk, ULGX is less volatile compared to INVO. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, TLIS has a market cap of 2.92M. Regarding current trading prices, ULGX is priced at $0.00, while TLIS trades at $1.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas TLIS's P/E ratio is -0.06. In terms of profitability, ULGX's ROE is +2.32%, compared to TLIS's ROE of -0.61%. Regarding short-term risk, ULGX is less volatile compared to TLIS. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, VTAK has a market cap of 2.66M. Regarding current trading prices, ULGX is priced at $0.00, while VTAK trades at $0.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas VTAK's P/E ratio is -0.04. In terms of profitability, ULGX's ROE is +2.32%, compared to VTAK's ROE of -1.16%. Regarding short-term risk, ULGX is less volatile compared to VTAK. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, BJDX has a market cap of 2.61M. Regarding current trading prices, ULGX is priced at $0.00, while BJDX trades at $1.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas BJDX's P/E ratio is -0.02. In terms of profitability, ULGX's ROE is +2.32%, compared to BJDX's ROE of -1.24%. Regarding short-term risk, ULGX is less volatile compared to BJDX. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, BBLG has a market cap of 2.45M. Regarding current trading prices, ULGX is priced at $0.00, while BBLG trades at $0.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas BBLG's P/E ratio is -0.16. In terms of profitability, ULGX's ROE is +2.32%, compared to BBLG's ROE of -2.11%. Regarding short-term risk, ULGX is less volatile compared to BBLG. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, TIVC has a market cap of 2.44M. Regarding current trading prices, ULGX is priced at $0.00, while TIVC trades at $3.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas TIVC's P/E ratio is -0.20. In terms of profitability, ULGX's ROE is +2.32%, compared to TIVC's ROE of -1.93%. Regarding short-term risk, ULGX is less volatile compared to TIVC. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, BBLGW has a market cap of 2.36M. Regarding current trading prices, ULGX is priced at $0.00, while BBLGW trades at $20.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas BBLGW's P/E ratio is -140.28. In terms of profitability, ULGX's ROE is +2.32%, compared to BBLGW's ROE of -2.11%. Regarding short-term risk, ULGX is less volatile compared to BBLGW. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, HSDT has a market cap of 2.30M. Regarding current trading prices, ULGX is priced at $0.00, while HSDT trades at $4.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas HSDT's P/E ratio is -0.16. In terms of profitability, ULGX's ROE is +2.32%, compared to HSDT's ROE of -3.56%. Regarding short-term risk, ULGX is less volatile compared to HSDT. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, PMEDF has a market cap of 2.25M. Regarding current trading prices, ULGX is priced at $0.00, while PMEDF trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas PMEDF's P/E ratio is -1.50. In terms of profitability, ULGX's ROE is +2.32%, compared to PMEDF's ROE of +1.68%. Regarding short-term risk, ULGX is less volatile compared to PMEDF. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, LLBO has a market cap of 2.17M. Regarding current trading prices, ULGX is priced at $0.00, while LLBO trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas LLBO's P/E ratio is N/A. In terms of profitability, ULGX's ROE is +2.32%, compared to LLBO's ROE of +0.00%. Regarding short-term risk, ULGX and LLBO have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, SIEN has a market cap of 2.08M. Regarding current trading prices, ULGX is priced at $0.00, while SIEN trades at $0.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas SIEN's P/E ratio is -0.03. In terms of profitability, ULGX's ROE is +2.32%, compared to SIEN's ROE of +0.96%. Regarding short-term risk, ULGX is less volatile compared to SIEN. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, CUTR has a market cap of 1.96M. Regarding current trading prices, ULGX is priced at $0.00, while CUTR trades at $0.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas CUTR's P/E ratio is -0.01. In terms of profitability, ULGX's ROE is +2.32%, compared to CUTR's ROE of +0.63%. Regarding short-term risk, ULGX is less volatile compared to CUTR. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, USAQ has a market cap of 1.92M. Regarding current trading prices, ULGX is priced at $0.00, while USAQ trades at $0.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas USAQ's P/E ratio is -5.66. In terms of profitability, ULGX's ROE is +2.32%, compared to USAQ's ROE of +0.61%. Regarding short-term risk, ULGX is less volatile compared to USAQ. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, ALRTF has a market cap of 1.91M. Regarding current trading prices, ULGX is priced at $0.00, while ALRTF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas ALRTF's P/E ratio is -0.10. In terms of profitability, ULGX's ROE is +2.32%, compared to ALRTF's ROE of +0.52%. Regarding short-term risk, ULGX is less volatile compared to ALRTF. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, KLYG has a market cap of 1.83M. Regarding current trading prices, ULGX is priced at $0.00, while KLYG trades at $0.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas KLYG's P/E ratio is -14.50. In terms of profitability, ULGX's ROE is +2.32%, compared to KLYG's ROE of -1.14%. Regarding short-term risk, ULGX and KLYG have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, CRRVF has a market cap of 1.54M. Regarding current trading prices, ULGX is priced at $0.00, while CRRVF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas CRRVF's P/E ratio is N/A. In terms of profitability, ULGX's ROE is +2.32%, compared to CRRVF's ROE of +0.00%. Regarding short-term risk, ULGX is less volatile compared to CRRVF. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, NAYA has a market cap of 1.47M. Regarding current trading prices, ULGX is priced at $0.00, while NAYA trades at $2.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas NAYA's P/E ratio is -0.18. In terms of profitability, ULGX's ROE is +2.32%, compared to NAYA's ROE of -13.32%. Regarding short-term risk, ULGX is less volatile compared to NAYA. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, ESMC has a market cap of 1.41M. Regarding current trading prices, ULGX is priced at $0.00, while ESMC trades at $0.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas ESMC's P/E ratio is 19.00. In terms of profitability, ULGX's ROE is +2.32%, compared to ESMC's ROE of +0.00%. Regarding short-term risk, ULGX is less volatile compared to ESMC. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, ZMSPF has a market cap of 1.23M. Regarding current trading prices, ULGX is priced at $0.00, while ZMSPF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas ZMSPF's P/E ratio is N/A. In terms of profitability, ULGX's ROE is +2.32%, compared to ZMSPF's ROE of +0.82%. Regarding short-term risk, ULGX is less volatile compared to ZMSPF. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, PETVW has a market cap of 1.20M. Regarding current trading prices, ULGX is priced at $0.00, while PETVW trades at $0.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas PETVW's P/E ratio is -0.10. In terms of profitability, ULGX's ROE is +2.32%, compared to PETVW's ROE of -28.07%. Regarding short-term risk, ULGX and PETVW have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, UAHC has a market cap of 1.19M. Regarding current trading prices, ULGX is priced at $0.00, while UAHC trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas UAHC's P/E ratio is 0.85. In terms of profitability, ULGX's ROE is +2.32%, compared to UAHC's ROE of +0.07%. Regarding short-term risk, ULGX and UAHC have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, CYDX has a market cap of 1.04M. Regarding current trading prices, ULGX is priced at $0.00, while CYDX trades at $0.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas CYDX's P/E ratio is 0.26. In terms of profitability, ULGX's ROE is +2.32%, compared to CYDX's ROE of +0.17%. Regarding short-term risk, ULGX and CYDX have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, ODYY has a market cap of 976769.00. Regarding current trading prices, ULGX is priced at $0.00, while ODYY trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas ODYY's P/E ratio is -0.06. In terms of profitability, ULGX's ROE is +2.32%, compared to ODYY's ROE of +5.81%. Regarding short-term risk, ULGX and ODYY have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, BRSF has a market cap of 931988.00. Regarding current trading prices, ULGX is priced at $0.00, while BRSF trades at $0.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas BRSF's P/E ratio is -0.06. In terms of profitability, ULGX's ROE is +2.32%, compared to BRSF's ROE of -6.82%. Regarding short-term risk, ULGX and BRSF have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, AFIB has a market cap of 897369.00. Regarding current trading prices, ULGX is priced at $0.00, while AFIB trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas AFIB's P/E ratio is -0.20. In terms of profitability, ULGX's ROE is +2.32%, compared to AFIB's ROE of +1.24%. Regarding short-term risk, ULGX is less volatile compared to AFIB. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, PAVMW has a market cap of 769747.00. Regarding current trading prices, ULGX is priced at $0.00, while PAVMW trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas PAVMW's P/E ratio is -0.05. In terms of profitability, ULGX's ROE is +2.32%, compared to PAVMW's ROE of -1.06%. Regarding short-term risk, ULGX is less volatile compared to PAVMW. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, BIOL has a market cap of 731942.00. Regarding current trading prices, ULGX is priced at $0.00, while BIOL trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas BIOL's P/E ratio is 0.00. In terms of profitability, ULGX's ROE is +2.32%, compared to BIOL's ROE of +122.67%. Regarding short-term risk, ULGX is less volatile compared to BIOL. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, DYNT has a market cap of 722447.00. Regarding current trading prices, ULGX is priced at $0.00, while DYNT trades at $0.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas DYNT's P/E ratio is -0.10. In terms of profitability, ULGX's ROE is +2.32%, compared to DYNT's ROE of -0.19%. Regarding short-term risk, ULGX is less volatile compared to DYNT. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, SONX has a market cap of 589813.00. Regarding current trading prices, ULGX is priced at $0.00, while SONX trades at $1.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas SONX's P/E ratio is -0.02. In terms of profitability, ULGX's ROE is +2.32%, compared to SONX's ROE of -1.91%. Regarding short-term risk, ULGX is less volatile compared to SONX. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, DHAIW has a market cap of 491532.00. Regarding current trading prices, ULGX is priced at $0.00, while DHAIW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas DHAIW's P/E ratio is N/A. In terms of profitability, ULGX's ROE is +2.32%, compared to DHAIW's ROE of +0.26%. Regarding short-term risk, ULGX and DHAIW have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, FLURF has a market cap of 447175.00. Regarding current trading prices, ULGX is priced at $0.00, while FLURF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas FLURF's P/E ratio is -0.15. In terms of profitability, ULGX's ROE is +2.32%, compared to FLURF's ROE of +9.70%. Regarding short-term risk, ULGX and FLURF have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, VRSEF has a market cap of 439380.00. Regarding current trading prices, ULGX is priced at $0.00, while VRSEF trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas VRSEF's P/E ratio is 0.14. In terms of profitability, ULGX's ROE is +2.32%, compared to VRSEF's ROE of +3.92%. Regarding short-term risk, ULGX is less volatile compared to VRSEF. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, GBS has a market cap of 433577.00. Regarding current trading prices, ULGX is priced at $0.00, while GBS trades at $0.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas GBS's P/E ratio is -0.94. In terms of profitability, ULGX's ROE is +2.32%, compared to GBS's ROE of -3.09%. Regarding short-term risk, ULGX is less volatile compared to GBS. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, SHOM has a market cap of 398670.00. Regarding current trading prices, ULGX is priced at $0.00, while SHOM trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas SHOM's P/E ratio is N/A. In terms of profitability, ULGX's ROE is +2.32%, compared to SHOM's ROE of N/A. Regarding short-term risk, ULGX and SHOM have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, LNDZF has a market cap of 332291.00. Regarding current trading prices, ULGX is priced at $0.00, while LNDZF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas LNDZF's P/E ratio is -0.02. In terms of profitability, ULGX's ROE is +2.32%, compared to LNDZF's ROE of +46.72%. Regarding short-term risk, ULGX is less volatile compared to LNDZF. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, IDYLF has a market cap of 310038.00. Regarding current trading prices, ULGX is priced at $0.00, while IDYLF trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas IDYLF's P/E ratio is -0.75. In terms of profitability, ULGX's ROE is +2.32%, compared to IDYLF's ROE of +0.27%. Regarding short-term risk, ULGX and IDYLF have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, CHYPF has a market cap of 302697.00. Regarding current trading prices, ULGX is priced at $0.00, while CHYPF trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas CHYPF's P/E ratio is -0.63. In terms of profitability, ULGX's ROE is +2.32%, compared to CHYPF's ROE of +0.15%. Regarding short-term risk, ULGX is less volatile compared to CHYPF. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, OSAAW has a market cap of 270202.00. Regarding current trading prices, ULGX is priced at $0.00, while OSAAW trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas OSAAW's P/E ratio is N/A. In terms of profitability, ULGX's ROE is +2.32%, compared to OSAAW's ROE of +0.57%. Regarding short-term risk, ULGX is less volatile compared to OSAAW. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, FORZ has a market cap of 252183.00. Regarding current trading prices, ULGX is priced at $0.00, while FORZ trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas FORZ's P/E ratio is -0.01. In terms of profitability, ULGX's ROE is +2.32%, compared to FORZ's ROE of +1.60%. Regarding short-term risk, ULGX and FORZ have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, OSAPQ has a market cap of 243517.00. Regarding current trading prices, ULGX is priced at $0.00, while OSAPQ trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas OSAPQ's P/E ratio is -0.01. In terms of profitability, ULGX's ROE is +2.32%, compared to OSAPQ's ROE of +0.42%. Regarding short-term risk, ULGX is less volatile compared to OSAPQ. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, PBIO has a market cap of 213029.00. Regarding current trading prices, ULGX is priced at $0.00, while PBIO trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas PBIO's P/E ratio is -0.01. In terms of profitability, ULGX's ROE is +2.32%, compared to PBIO's ROE of +0.70%. Regarding short-term risk, ULGX is less volatile compared to PBIO. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, VRSYF has a market cap of 156166.00. Regarding current trading prices, ULGX is priced at $0.00, while VRSYF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas VRSYF's P/E ratio is N/A. In terms of profitability, ULGX's ROE is +2.32%, compared to VRSYF's ROE of -0.20%. Regarding short-term risk, ULGX is less volatile compared to VRSYF. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, EMDF has a market cap of 131938.00. Regarding current trading prices, ULGX is priced at $0.00, while EMDF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas EMDF's P/E ratio is -0.31. In terms of profitability, ULGX's ROE is +2.32%, compared to EMDF's ROE of +0.00%. Regarding short-term risk, ULGX and EMDF have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, SNDD has a market cap of 131690.00. Regarding current trading prices, ULGX is priced at $0.00, while SNDD trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas SNDD's P/E ratio is -0.00. In terms of profitability, ULGX's ROE is +2.32%, compared to SNDD's ROE of +1.75%. Regarding short-term risk, ULGX and SNDD have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, AQQRF has a market cap of 115917.00. Regarding current trading prices, ULGX is priced at $0.00, while AQQRF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas AQQRF's P/E ratio is -0.42. In terms of profitability, ULGX's ROE is +2.32%, compared to AQQRF's ROE of +0.18%. Regarding short-term risk, ULGX and AQQRF have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, TBIO has a market cap of 108504.00. Regarding current trading prices, ULGX is priced at $0.00, while TBIO trades at $0.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas TBIO's P/E ratio is N/A. In terms of profitability, ULGX's ROE is +2.32%, compared to TBIO's ROE of -2.80%. Regarding short-term risk, ULGX and TBIO have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, SSUR has a market cap of 107057.00. Regarding current trading prices, ULGX is priced at $0.00, while SSUR trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas SSUR's P/E ratio is N/A. In terms of profitability, ULGX's ROE is +2.32%, compared to SSUR's ROE of N/A. Regarding short-term risk, ULGX and SSUR have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, ARMM has a market cap of 106247.00. Regarding current trading prices, ULGX is priced at $0.00, while ARMM trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas ARMM's P/E ratio is N/A. In terms of profitability, ULGX's ROE is +2.32%, compared to ARMM's ROE of N/A. Regarding short-term risk, ULGX and ARMM have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, CKNTF has a market cap of 100000.00. Regarding current trading prices, ULGX is priced at $0.00, while CKNTF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas CKNTF's P/E ratio is N/A. In terms of profitability, ULGX's ROE is +2.32%, compared to CKNTF's ROE of N/A. Regarding short-term risk, ULGX and CKNTF have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, EMED has a market cap of 85504.00. Regarding current trading prices, ULGX is priced at $0.00, while EMED trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas EMED's P/E ratio is -0.01. In terms of profitability, ULGX's ROE is +2.32%, compared to EMED's ROE of +0.48%. Regarding short-term risk, ULGX and EMED have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, NXNN has a market cap of 78625.00. Regarding current trading prices, ULGX is priced at $0.00, while NXNN trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas NXNN's P/E ratio is -0.00. In terms of profitability, ULGX's ROE is +2.32%, compared to NXNN's ROE of -0.19%. Regarding short-term risk, ULGX and NXNN have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, WLSI has a market cap of 73713.00. Regarding current trading prices, ULGX is priced at $0.00, while WLSI trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas WLSI's P/E ratio is N/A. In terms of profitability, ULGX's ROE is +2.32%, compared to WLSI's ROE of +0.06%. Regarding short-term risk, ULGX is less volatile compared to WLSI. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, MHTX has a market cap of 55928.00. Regarding current trading prices, ULGX is priced at $0.00, while MHTX trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas MHTX's P/E ratio is -0.01. In terms of profitability, ULGX's ROE is +2.32%, compared to MHTX's ROE of +0.38%. Regarding short-term risk, ULGX and MHTX have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, HSCSW has a market cap of 43238.00. Regarding current trading prices, ULGX is priced at $0.00, while HSCSW trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas HSCSW's P/E ratio is -0.04. In terms of profitability, ULGX's ROE is +2.32%, compared to HSCSW's ROE of -1.75%. Regarding short-term risk, ULGX and HSCSW have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, ABMT has a market cap of 40000.00. Regarding current trading prices, ULGX is priced at $0.00, while ABMT trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas ABMT's P/E ratio is -0.04. In terms of profitability, ULGX's ROE is +2.32%, compared to ABMT's ROE of +0.06%. Regarding short-term risk, ULGX is less volatile compared to ABMT. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, RTSL has a market cap of 35329.00. Regarding current trading prices, ULGX is priced at $0.00, while RTSL trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas RTSL's P/E ratio is 0.40. In terms of profitability, ULGX's ROE is +2.32%, compared to RTSL's ROE of +0.75%. Regarding short-term risk, ULGX and RTSL have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, ECGI has a market cap of 15504.00. Regarding current trading prices, ULGX is priced at $0.00, while ECGI trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas ECGI's P/E ratio is -0.09. In terms of profitability, ULGX's ROE is +2.32%, compared to ECGI's ROE of -0.32%. Regarding short-term risk, ULGX is less volatile compared to ECGI. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, CGHC has a market cap of 14752.00. Regarding current trading prices, ULGX is priced at $0.00, while CGHC trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas CGHC's P/E ratio is N/A. In terms of profitability, ULGX's ROE is +2.32%, compared to CGHC's ROE of +0.61%. Regarding short-term risk, ULGX is less volatile compared to CGHC. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, MGFRF has a market cap of 11973.00. Regarding current trading prices, ULGX is priced at $0.00, while MGFRF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas MGFRF's P/E ratio is -0.00. In terms of profitability, ULGX's ROE is +2.32%, compared to MGFRF's ROE of +0.00%. Regarding short-term risk, ULGX is less volatile compared to MGFRF. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, PAVMZ has a market cap of 11923.00. Regarding current trading prices, ULGX is priced at $0.00, while PAVMZ trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas PAVMZ's P/E ratio is N/A. In terms of profitability, ULGX's ROE is +2.32%, compared to PAVMZ's ROE of -1.06%. Regarding short-term risk, ULGX is less volatile compared to PAVMZ. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, WCUI has a market cap of 11560.00. Regarding current trading prices, ULGX is priced at $0.00, while WCUI trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas WCUI's P/E ratio is -0.01. In terms of profitability, ULGX's ROE is +2.32%, compared to WCUI's ROE of +0.20%. Regarding short-term risk, ULGX and WCUI have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, NNMX has a market cap of 9799.00. Regarding current trading prices, ULGX is priced at $0.00, while NNMX trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas NNMX's P/E ratio is -0.00. In terms of profitability, ULGX's ROE is +2.32%, compared to NNMX's ROE of +1.28%. Regarding short-term risk, ULGX and NNMX have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, TCLIF has a market cap of 7877.00. Regarding current trading prices, ULGX is priced at $0.00, while TCLIF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas TCLIF's P/E ratio is N/A. In terms of profitability, ULGX's ROE is +2.32%, compared to TCLIF's ROE of -0.63%. Regarding short-term risk, ULGX is less volatile compared to TCLIF. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, EQUR has a market cap of 6909.00. Regarding current trading prices, ULGX is priced at $0.00, while EQUR trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas EQUR's P/E ratio is -0.01. In terms of profitability, ULGX's ROE is +2.32%, compared to EQUR's ROE of +1.75%. Regarding short-term risk, ULGX and EQUR have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, MSIU has a market cap of 5101.00. Regarding current trading prices, ULGX is priced at $0.00, while MSIU trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas MSIU's P/E ratio is -0.01. In terms of profitability, ULGX's ROE is +2.32%, compared to MSIU's ROE of -3.07%. Regarding short-term risk, ULGX and MSIU have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, SNDZ has a market cap of 4927.00. Regarding current trading prices, ULGX is priced at $0.00, while SNDZ trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas SNDZ's P/E ratio is N/A. In terms of profitability, ULGX's ROE is +2.32%, compared to SNDZ's ROE of +2.56%. Regarding short-term risk, ULGX and SNDZ have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, VIVE has a market cap of 4290.00. Regarding current trading prices, ULGX is priced at $0.00, while VIVE trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas VIVE's P/E ratio is N/A. In terms of profitability, ULGX's ROE is +2.32%, compared to VIVE's ROE of -2.00%. Regarding short-term risk, ULGX and VIVE have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, NMRD has a market cap of 4035.00. Regarding current trading prices, ULGX is priced at $0.00, while NMRD trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas NMRD's P/E ratio is N/A. In terms of profitability, ULGX's ROE is +2.32%, compared to NMRD's ROE of +2.49%. Regarding short-term risk, ULGX is less volatile compared to NMRD. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, AHPIQ has a market cap of 4010.00. Regarding current trading prices, ULGX is priced at $0.00, while AHPIQ trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas AHPIQ's P/E ratio is -0.00. In terms of profitability, ULGX's ROE is +2.32%, compared to AHPIQ's ROE of N/A. Regarding short-term risk, ULGX and AHPIQ have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, EVARF has a market cap of 2795.00. Regarding current trading prices, ULGX is priced at $0.00, while EVARF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas EVARF's P/E ratio is N/A. In terms of profitability, ULGX's ROE is +2.32%, compared to EVARF's ROE of -1.09%. Regarding short-term risk, ULGX is less volatile compared to EVARF. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, LPTI has a market cap of 2308.00. Regarding current trading prices, ULGX is priced at $0.00, while LPTI trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas LPTI's P/E ratio is N/A. In terms of profitability, ULGX's ROE is +2.32%, compared to LPTI's ROE of N/A. Regarding short-term risk, ULGX is less volatile compared to LPTI. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, VRAYQ has a market cap of 1834.00. Regarding current trading prices, ULGX is priced at $0.00, while VRAYQ trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas VRAYQ's P/E ratio is N/A. In terms of profitability, ULGX's ROE is +2.32%, compared to VRAYQ's ROE of N/A. Regarding short-term risk, ULGX is less volatile compared to VRAYQ. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, THMO has a market cap of 1585.00. Regarding current trading prices, ULGX is priced at $0.00, while THMO trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas THMO's P/E ratio is N/A. In terms of profitability, ULGX's ROE is +2.32%, compared to THMO's ROE of +25.64%. Regarding short-term risk, ULGX and THMO have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, VICA has a market cap of 1572.00. Regarding current trading prices, ULGX is priced at $0.00, while VICA trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas VICA's P/E ratio is -0.01. In terms of profitability, ULGX's ROE is +2.32%, compared to VICA's ROE of +0.00%. Regarding short-term risk, ULGX and VICA have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, AVTI has a market cap of 1382.00. Regarding current trading prices, ULGX is priced at $0.00, while AVTI trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas AVTI's P/E ratio is N/A. In terms of profitability, ULGX's ROE is +2.32%, compared to AVTI's ROE of +0.25%. Regarding short-term risk, ULGX is less volatile compared to AVTI. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, MMTC has a market cap of 901.00. Regarding current trading prices, ULGX is priced at $0.00, while MMTC trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas MMTC's P/E ratio is N/A. In terms of profitability, ULGX's ROE is +2.32%, compared to MMTC's ROE of N/A. Regarding short-term risk, ULGX and MMTC have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, IGNT has a market cap of 896.00. Regarding current trading prices, ULGX is priced at $0.00, while IGNT trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas IGNT's P/E ratio is N/A. In terms of profitability, ULGX's ROE is +2.32%, compared to IGNT's ROE of +1.99%. Regarding short-term risk, ULGX is less volatile compared to IGNT. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, LCDX has a market cap of 851.00. Regarding current trading prices, ULGX is priced at $0.00, while LCDX trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas LCDX's P/E ratio is N/A. In terms of profitability, ULGX's ROE is +2.32%, compared to LCDX's ROE of N/A. Regarding short-term risk, ULGX and LCDX have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, SWNM has a market cap of 829.00. Regarding current trading prices, ULGX is priced at $0.00, while SWNM trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas SWNM's P/E ratio is N/A. In terms of profitability, ULGX's ROE is +2.32%, compared to SWNM's ROE of N/A. Regarding short-term risk, ULGX is less volatile compared to SWNM. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, BIIO has a market cap of 775.00. Regarding current trading prices, ULGX is priced at $0.00, while BIIO trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas BIIO's P/E ratio is N/A. In terms of profitability, ULGX's ROE is +2.32%, compared to BIIO's ROE of +0.00%. Regarding short-term risk, ULGX is less volatile compared to BIIO. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, MOTS has a market cap of 639.00. Regarding current trading prices, ULGX is priced at $0.00, while MOTS trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas MOTS's P/E ratio is N/A. In terms of profitability, ULGX's ROE is +2.32%, compared to MOTS's ROE of -1.71%. Regarding short-term risk, ULGX and MOTS have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, NWCI has a market cap of 331.00. Regarding current trading prices, ULGX is priced at $0.00, while NWCI trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas NWCI's P/E ratio is N/A. In terms of profitability, ULGX's ROE is +2.32%, compared to NWCI's ROE of +4.96%. Regarding short-term risk, ULGX is less volatile compared to NWCI. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, HLTHQ has a market cap of 159.00. Regarding current trading prices, ULGX is priced at $0.00, while HLTHQ trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas HLTHQ's P/E ratio is N/A. In terms of profitability, ULGX's ROE is +2.32%, compared to HLTHQ's ROE of -0.88%. Regarding short-term risk, ULGX is less volatile compared to HLTHQ. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, ENCW has a market cap of 111.00. Regarding current trading prices, ULGX is priced at $0.00, while ENCW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas ENCW's P/E ratio is -0.01. In terms of profitability, ULGX's ROE is +2.32%, compared to ENCW's ROE of N/A. Regarding short-term risk, ULGX and ENCW have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, PECN has a market cap of 101.00. Regarding current trading prices, ULGX is priced at $0.00, while PECN trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas PECN's P/E ratio is -0.00. In terms of profitability, ULGX's ROE is +2.32%, compared to PECN's ROE of N/A. Regarding short-term risk, ULGX is less volatile compared to PECN. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, HRTT has a market cap of 55.00. Regarding current trading prices, ULGX is priced at $0.00, while HRTT trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas HRTT's P/E ratio is -0.00. In terms of profitability, ULGX's ROE is +2.32%, compared to HRTT's ROE of -4.52%. Regarding short-term risk, ULGX and HRTT have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, RFCS has a market cap of 25.00. Regarding current trading prices, ULGX is priced at $0.00, while RFCS trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas RFCS's P/E ratio is N/A. In terms of profitability, ULGX's ROE is +2.32%, compared to RFCS's ROE of N/A. Regarding short-term risk, ULGX and RFCS have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, QTNT comparison data is unavailable. Regarding current trading prices, ULGX is priced at $0.00, while QTNT trades at $0.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas QTNT's P/E ratio is N/A. In terms of profitability, ULGX's ROE is +2.32%, compared to QTNT's ROE of +1.45%. Regarding short-term risk, ULGX is less volatile compared to QTNT. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, SOLY comparison data is unavailable. Regarding current trading prices, ULGX is priced at $0.00, while SOLY trades at $22.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas SOLY's P/E ratio is N/A. In terms of profitability, ULGX's ROE is +2.32%, compared to SOLY's ROE of -0.70%. Regarding short-term risk, ULGX is less volatile compared to SOLY. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, SRGA comparison data is unavailable. Regarding current trading prices, ULGX is priced at $0.00, while SRGA trades at $0.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas SRGA's P/E ratio is -0.02. In terms of profitability, ULGX's ROE is +2.32%, compared to SRGA's ROE of +6.24%. Regarding short-term risk, ULGX is less volatile compared to SRGA. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, AHPI comparison data is unavailable. Regarding current trading prices, ULGX is priced at $0.00, while AHPI trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas AHPI's P/E ratio is -0.00. In terms of profitability, ULGX's ROE is +2.32%, compared to AHPI's ROE of -0.68%. Regarding short-term risk, ULGX and AHPI have similar daily volatility (0.00).

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, ISR comparison data is unavailable. Regarding current trading prices, ULGX is priced at $0.00, while ISR trades at $0.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas ISR's P/E ratio is N/A. In terms of profitability, ULGX's ROE is +2.32%, compared to ISR's ROE of -0.49%. Regarding short-term risk, ULGX is less volatile compared to ISR. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, SPNE comparison data is unavailable. Regarding current trading prices, ULGX is priced at $0.00, while SPNE trades at $9.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas SPNE's P/E ratio is N/A. In terms of profitability, ULGX's ROE is +2.32%, compared to SPNE's ROE of -0.22%. Regarding short-term risk, ULGX is less volatile compared to SPNE. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, MSON comparison data is unavailable. Regarding current trading prices, ULGX is priced at $0.00, while MSON trades at $26.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas MSON's P/E ratio is N/A. In terms of profitability, ULGX's ROE is +2.32%, compared to MSON's ROE of -0.10%. Regarding short-term risk, ULGX is less volatile compared to MSON. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, XENT comparison data is unavailable. Regarding current trading prices, ULGX is priced at $0.00, while XENT trades at $28.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas XENT's P/E ratio is -10.54. In terms of profitability, ULGX's ROE is +2.32%, compared to XENT's ROE of +155.21%. Regarding short-term risk, ULGX is less volatile compared to XENT. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, ITMR comparison data is unavailable. Regarding current trading prices, ULGX is priced at $0.00, while ITMR trades at $30.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas ITMR's P/E ratio is -21.00. In terms of profitability, ULGX's ROE is +2.32%, compared to ITMR's ROE of -0.37%. Regarding short-term risk, ULGX is less volatile compared to ITMR. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.

ULGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ULGX stands at 2182.00. In comparison, NTUS comparison data is unavailable. Regarding current trading prices, ULGX is priced at $0.00, while NTUS trades at $32.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ULGX currently has a P/E ratio of -0.01, whereas NTUS's P/E ratio is 86.74. In terms of profitability, ULGX's ROE is +2.32%, compared to NTUS's ROE of +0.03%. Regarding short-term risk, ULGX is less volatile compared to NTUS. This indicates potentially lower risk in terms of short-term price fluctuations for ULGX.